Genetic background of relapsing lymphoid neoplasms : comprehensive genetic characterization of primary - relapse pairs by chromosomal copy number and mutational analysis by Juškevičius, Darius
Genetic background of relapsing lymphoid neoplasms: 
comprehensive genetic characterization of primary-
relapse pairs by chromosomal copy number and 
mutational analysis 
 
 
 
 
Inauguraldissertation 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
 
Darius Juškevičius 
aus Litauen 
 
 
 
 
 
 
Basel, 2016 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel 
edoc.unibas.ch 
 
Dissertation    Darius Juškevičius 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von 
Prof. Dr. Nancy Hynes 
Prof. Dr. Jürg Schwaller 
Prof. Dr. Alexandar Tzankov 
 
 
Basel, den 23. Februar 2016 
 
 
 
 
 
 
       Prof. Dr. Jörg Schilber 
       Dekan 
I dedicate this work to my wife Reda and to my parents 
  
  
 
 TABLE OF CONTENTS 
SUMMARY .................................................................................................................................... 1 
1. INTRODUCTION ................................................................................................................... 3 
1.1 B-cell development ................................................................................................................ 3 
1.1.1 Early stages of B-cell development ................................................................................ 3 
1.1.2 Structural organization and rearrangement of IG genes. ................................................ 6 
1.1.3 The germinal center reaction and parafollicular activation of B-blasts ......................... 8 
1.2 Diffuse large B-cell lymphoma, not otherwise specified (NOS) ........................................ 15 
1.2.1 Molecular pathogenesis of DLBCL ............................................................................. 17 
1.2.3 Treatment of DLBCL ................................................................................................... 24 
1.2.4 Prognostic and predictive markers in DLBCL ............................................................. 27 
1.2.5 Clinical importance and biological background of DLBCL relapses .......................... 29 
1.2.6 Clonal relationship in relapsing lymphomas ................................................................ 31 
2. AIMS ..................................................................................................................................... 34 
3. RESULTS .............................................................................................................................. 36 
3.1 Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by 
genome wide copy number aberration and targeted sequencing analysis. ................................ 36 
3.2 Extracavitary primary effusion lymphoma: clinical, morphological, phenotypic and 
cytogenetic characterization using nuclei enrichment technique. ............................................. 71 
3.3 Follicular lymphoma transformation into histiocytic sarcoma: indications for a common 
neoplastic progenitor ................................................................................................................. 86 
3.4 Clinical, morphologic, phenotypic, and genetic evidence of cyclin D1-positive diffuse 
large B-cell lymphomas with CYCLIN D1 gene rearrangements ............................................ 90 
3.5 Array CGH-based analysis of post-transplant plasmacytic hyperplasia reveals 'intact 
genomes' arguing against categorizing it as part of the post-transplant lymphoproliferative 
disease spectrum. ..................................................................................................................... 100 
3.6 Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or 
NF-κB signaling instead of B-cell receptor signaling ............................................................. 104 
3.7 Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-
transplant lymphoproliferative disorder .................................................................................. 116 
3.8 Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell 
lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the 
prospective SAKK 38/07 ........................................................................................................ 121 
4. DISCUSSION ..................................................................................................................... 133 
4.1 Clonally-unrelated relapses of DLBCL............................................................................. 133 
4.2 DLBCL relapses occur via two distinct genetic evolution patterns .................................. 134 
4.3 Identification of genetic drivers of DLBCL relapse .......................................................... 140 
Dissertation    Darius Juškevičius 
 
4.4 Branching evolution and hematopoietic plasticity of follicular lymphoma relapse and its 
transformation to histiocytic sarcoma ..................................................................................... 143 
4.5. Sorting of FFPE-tissue derived tumor nuclei enables genetic investigation of rare cancer 
cell populations ....................................................................................................................... 145 
GENERAL CONCLUSION ....................................................................................................... 147 
REFERENCES............................................................................................................................ 149 
LIST OF ABBREVIATIONS ..................................................................................................... 160 
CURRICULUM VITAE ............................................................................................................. 162 
ACKNOWLEDGEMENTS ........................................................................................................ 164 
 
 
 
SUMMARY 
 
1 
 
SUMMARY 
Diffuse large B-cell lymphoma (DLBCL) is the most frequent tumor of the lymphoid system. 
Standard first line therapy is successful in the majority of cases, however about 30% of DLBCL 
are either refractory to it or relapse after a period of remission. Therapy options for such patients 
are very limited and disease outcomes are often unfavorable. Recent years of research have 
considerably advanced our understanding of molecular processes that drive lymphomagenesis of 
primary DLBCL. However, due to lack of focused studies, knowledge on the genetic basis of 
DLBCL relapse remains scarce. It is largely unknown how tumors evolve under treatment, which 
genetic events lead to recurrence, how resistance emerges and whether relapses can be reliably 
predicted at the timepoint of initial diagnosis. 
We sought to address these questions by comprehensive genetic analysis of two retrospective 
DLBCL cohorts. One consisted of paired primary and relapse samples from 20 relapsing 
DLBCL cases, another of 11 non-relapsing primary DLBCL samples. We performed histological 
characterization, investigated genome-wide DNA copy number aberrations and most common 
nucleotide-level alterations, and tested clonal relationships between paired tumors of the same 
patient. Our study provided important novel findings and strengthened some previous 
observations.  
Clonally-unrelated DLBCL relapses were previously equivocally documented by demonstration 
of distinct immunoglobuln gene (IG) rearrangements between the first and the second lymphoma 
occurrence. We support this observation and provide high quality evidence showing not only 
distinct IG rearrangements, but also lack of unifying genetic alterations throughout the whole 
tumors’ genomes of clonally-unrelated relapses. Therefore we propose to call such 
manifestations second de novo DLBCL occurring in the same individual. 
Genetic evolution of DLBCL at relapse is largely unexplored except of a single study, but much 
is assumed from results and conclusions in other lymphoid neoplasms. Analysis of the dynamics 
of shared and private alterations in paired tumors suggested existence of at least two distinct 
patterns of genome evolution at relapse. About one third of investigated clonally-related cases 
followed an early-divergent/branching pattern of a relapse, characterized by a small number of 
shared mutations between the two occurrences and a large number of primary tumor-specific 
alterations. The rest of the cases relapsed via a late-divergent/linear pattern. They were 
characterized by sharing most mutations between the respective primaries and relapses and very 
small numbers, if any, of primary tumor-specific genetic alterations.  
Dissertation    Darius Juškevičius 
 
2 
 
The identification of precise genetic drivers and prognostic factors of relapse is challenged by an 
extreme heterogeneity of DLBCL. Together with the small sample sizes of analyzed collectives, 
this is probably the main reason why there is only a limited overlap in findings between studies, 
addressing this issue up to date. Our analysis identified two genes, KMT2D and MEF2B, which 
recurrently gained additional mutations at relapse. Further, we identified recurrently shared 
alterations of CD79B, KMT2D, MYD88, PIM1, which represented early drivers of 
lymphomagenesis. Finally, comparing genetic data between relapsing and non-relapsing DLBCL 
cohorts we identified group-specific DNA lesions (recurrent gains of 10p15.3-13 containing 
GATA3 and PRKCQ in primary relapsing DLBCL and mutations of SOCS1 and RELN in non-
relapsing DLBCL). The prognostic power of them could be further investigated in dedicated 
large-scale studies. 
We are committed in further analyzing paired lymphoma samples, also in difficult settings, as 
demonstrated by two small-scale studies included in this dissertation. We developed and applied 
a technique to enrich rare lymphoma cells from formalin-fixed paraffin-embedded tissues. It 
enables meaningful genetic analysis of relapses in lymphoid neoplasms, such as classical 
Hodgkin lymphoma, which are important but understudied, due to their research-limiting 
morphological properties. 
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1. INTRODUCTION 
1.1 B-cell development 
1.1.1 Early stages of B-cell development 
B-lymphocytes (B-cells) are a population of cells expressing clonally diverse cell surface 
immunoglobulin (Ig) receptors, which recognize specific antigens. B-cells develop from the 
hematopoietic precursor cells that reside in the bone marrow. Their development involves 
multiple stages beginning with the emergence of lineage in the primary lymphoid tissue (e.g. 
fetal liver, adult bone marrow) and continuing with functional maturation in secondary 
lymphoid organs (the spleen, lymph nodes, Peyer’s patches, mucosal tissues etc.). B-cells 
terminally differentiate into either memory cells, which can initiate a secondary immune 
response or into non-proliferating plasma cells The functional endpoint of B-cell development 
is the production of antigen-specific antibodies
1
 (Figure 1). 
During embryogenesis, bone marrow is seeded by the hematopoietic stem cells from the 
developing fetal liver. It provides complex and dynamic microenvironment, or niche, required 
for the development of hematopoietic cells. A crucial role hereby play different types of bone 
marrow stromal cells that support B-cell differentiation in two major ways: first, by 
expressing specific types of adhesion molecules they assure physical localization of 
developing B-cells to the appropriate bone marrow compartments; second, they secrete 
cytokines that transfer key signals for B-cell differentiation
2
.  
Early bone marrow-dependent stages of B-cell development are structured around the 
rearrangements of immunoglobulin genes (IG). These early B-cell precursors also have a 
characteristic pattern of expressed surface markers and activated transcription factors. The 
expression of the B-lineage marker CD45D and increased amount of the transcription factor 
EBF1 marks the entrance of the developing lymphoid cell into the pre-pro B-cell stage
3
. At 
this stage EBF1 binds to the immunoglobulin heavy chain (IGH) gene and prepare it for D to 
JH recombination. Also, its expression is required for the later initiation of CD79A and 
CD79B production. Both of these molecules are essential components of the B-cell receptor 
(BCR)
4
.  
D to JH recombination is completed in the early pro-B cell stage. At this stage, activated by 
the binding of EBF1 to its promoter, the expression of PAX5 starts. PAX5 is a key B-cell 
transcription factor that is present in all B-cells throughout all subsequent developmental 
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stages until differentiation into plasma cells
5
. It is experimentally proven, that PAX5 is 
essential for the V to DJH recombination since mice lacking PAX5 are unable to complete the 
second stage of IG heavy chain rearrangement
6
. Also, during the pro-B cell stage CD79A/B 
are produced and PAX5 initiates the expression of the surface marker CD19, which itself is 
another essential component of the BCR and a widely used diagnostic marker for the B-cell 
lineage
5
. Furthermore, PAX5 is of paramount importance to the B-cells and is required for the 
full commitment of the hematopoietic progenitor cells to the B-cell fate, probably due to its 
ability to suppress expression of NOTCH1
7,8
.  
VDJH rearrangement is completed at the end of the pro-B cell stage and the expression of the 
pre-B cell receptor (pre-BCR) marks the entry to the early pre-B-cell developmental stage. 
Pre-BCR is composed of freshly rearranged IGH and surrogate light chain components VpreB 
and λ5. Pre-BCR signaling downregulates RAG1/2 enzymes and prevent further IGH 
rearrangements. The second IGH allele is suppressed due to allelic exclusion. Cells that fail to 
display a pre-BCR at this stage undergo controlled cell death by apoptosis, representing the 
Figure 1. Development of B-cells is a step-wise process that occurs in multiple distinct organism sites. 
Early stages take place in bone marrow where progenitor cells commit to a B-cell lineage, rearrange their 
immunoglobulin genes and start expressing a B-cell receptor. Immature B-cells migrate to the spleen to 
become transitional cells, which give raise to either naïve follicular B-cells or marginal zone B-cells. 
Follicular B-cells can form germinal centers and differentiate into memory B-cells or plasma cells 
Adapted from ref
10
. 
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first checkpoint in the B-cell development. Cells that successfully pass the first checkpoint 
undergo several rounds of proliferation before continuing with the rearrangement of the IG 
light chain genes. This leads to a possibility of several B-cell clones with identical IGH 
rearrangements but distinctly rearranged light chains.  
After successful proliferation the pre-BCR receptor is lost and this marks the entry to the late 
pre-B-cell stage. At this stage the expression of RAG1/2 is reactivated and the cells prepare 
for light-chain gene rearrangement. First κ light chain genes are rearranged. If rearrangements 
are non-productive, λ light chain alleles are rearranged9. After successful rearrangement the 
IgM receptor is displayed on the surface of B-cell. IgM expression is characteristic to the 
immature B-cells.  
Immature B-cells are tested for their reactivity against self-antigens in the bone marrow. 
Cells, which show self-reactivity, either undergo apoptosis (a process called clonal depletion) 
or editing of the IG. Non-reactive immature B cells leave the bone marrow and circulate to the 
spleen where they emerge as transitional 1 (T1) cells. Here T1 cells are once more tested for 
their reactivity against self-antigens present in the spleen. Again, self-reactive cells undergo 
apoptosis or edit their rearranged heavy- or light-chain genes. After this stage non-reactive 
cells enter spleen follicles where mRNA splicing is activated. Due to splicing B-cells start 
expressing IgD as a part of BCR, thus decreasing the amount of surface IgM receptors
10
.  
Besides the BCR signaling, the survival of B-cells in the periphery is dependent on signaling 
by the B-cell activator of the TNF-α family (BAFF). The BAFF receptor (BAFF-R) is first 
expressed at the end of the immature B-cell stage
11
. BAFF signaling promotes the expression 
of anti-apoptotic molecules such as BCL-2 and BCL-xl, providing survival signals to T1, T2 
and mature B-cells. Also BAFF is involved in non-canonical NF-B activation12,13. In mice, 
knockout of Baff-r or Baff results in decreased mature B-cell counts and weakened immune 
response – a phenotype, which can be reversed by overexpression of Bcl-214.  
Fully mature B cells that leave the spleen and recirculate between blood and lymphoid 
follicles in the lymphoid organs are called follicular B-2 cells. They express high levels of 
IgD and moderate levels of IgM and are ready to be activated if encountering foreign antigens 
fitting to their BCR. T2 cells also give rise to marginal zone B cells that are located in the 
outer regions of the white pulp of the spleen
1
. Recirculating follicular B-cells constitute the 
majority of mature B-cells and are the relevant type in the context of the majority of B-cell 
lymphomas, therefore further description of the B-cell maturation will be focused on them.  
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1.1.2 Structural organization and rearrangement of IG genes. 
Immunoglobulins (Ig) are formed by four separate polypeptides: two identical heavy chains 
and two identical light chains. Those polypeptides are coded by separate loci within the 
human genome. Heavy chain gene locus is located on chromosome (chr) 14, while the λ and κ 
light chain genes loci are located on chr 22 and chr 2, respectively. Germline IG have a 
unique multigene structure, which needs to be rearranged before production of functional Ig is 
possible. Such rearrangement process is restricted to B-cells in humans. Similar processes 
take place to rearrange receptor genes in T cells. The multigene structure is the source of 
profound variation that gives a potential for large numbers of combinations and therefore 
diverse specificity of the Ig
15
. 
The organization of light and heavy chain genes is very similar. The light chain locus consists 
of variable (V) genes, joining (J) genes and constant (C) genes. Heavy chain genes 
additionally have a diversity (D) region between V and J segments. The number of genes in 
each cluster differs (Figure 2). V genes are separated into families based on their sequence 
similarity. If similarity of two genes is lower than 80%, those genes belong to different V 
gene family
16. V genes are always located at the 5’ end of each IG locus. While a typical V 
gene is about 300 bp long, they are interspersed by non-coding DNA sequences. 
Figure 2. Schematic representation of human IG loci. The scale of the boxes is approximate. Only 
functional genes are shown. Non-coding sequences are displayed in gray. Note that joining (J) regions in 
lambda light chain are located between the constant regions. enh – enhancer; L – leader exon; Adapted 
from ref
15
. 
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Consequently, one V cluster can be as long as 200 kb in a germline genome. Upstream of 
each V cluster there is a leader exon, which encodes a leader peptide required for Ig 
translation and its import into the endoplasmic reticulum. 5’ to each leader peptide lies a V 
gene promoter, which is required for transcription
15
.  
3’ to the V genes are several J segments. They are typically 30 to 50 bp long, separated from 
each other by non-coding sequences. D segments are located in between V and J segments. 
Constant (C) genes lie 3’ to the J segments. In the IGL locus, the C gene consists of only one 
exon, while in the IGH, C genes typically have five or six exons.  
Non-coding sequences neighboring and within the IG loci play an important role in regulation 
of recombination and gene expression. These sequences contain repressors, enhancers, switch 
regions and recognition motifs that are essential for successful recombination and later 
transcription of the gene
15
.  
During B-cell development, IG can potentially undergo two types of rearrangements: V(D)J 
recombination and class switch recombination (CSR)
1
. Only the former is essential for IG 
transcription and expression of functional Ig. CSR is shortly addressed later in the chapter 
concerning germinal center reaction.  
During the V(D)J recombination the 3’ end of one D gene is brought to the 5’ end of one J 
gene. This stage is called DJ joining. Then in a similar manner the 3’ end of one of the V 
genes is ligated to the 5’ end of the DJ cluster, resulting in complete VDJ construct17. The 
light chain is rearranged in the same way, except there is only one stage i.e. VJ joining. 
Mechanistically, rearrangement is made possible by an availability of specific non-coding 
DNA sequences called recombination signal sequences (RSS). RSS are very conserved blocks 
of 7 (heptamers) and 9 (nonamers) nucleotides that occur upstream and downstream of V, D 
and J genes. They also include less conserved spacers of either 12 or 23 bp. The specific 
distribution pattern of these elements allows precise excision and joining of the target 
sequences
16
. The best understood enzymes that are involved in the recombination process are 
called recombination-activating genes 1 and 2 (RAG1 and RAG2)
18
. They recognize the RSS 
sequences and induce DNA strand breaks at specific sites. End processing and joining is 
performed with the help of additional protein complex including Artemis, DNA ligase IV, 
Terminal deoxynucleotidyl transferase (TdT) and other components of non-homologous end 
joining machinery. Of these, the expression of RAG1/2 and TdT is restricted only to 
lymphoid cells
15
. 
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1.1.3 The germinal center reaction and parafollicular activation of B-blasts 
Germinal centers (GC) were first discovered in 1884 by Dr. Walter Flemming. He described 
them as transient and distinct micro-anatomical structures in secondary lymphoid organs that 
contain dividing cells
19
. GC form after antigen- and T-cell-dependent B-cell activation and 
their main function is the affinity maturation of the BCR. This involves dynamic processes of 
dedicated structure formation, intra- and intercellular signaling, positive and negative 
selection, cell death, migration and differentiation (Figure 3). 
Circulating naïve B-cells express chemokine receptor CXCR5 and are attracted to the 
lymphoid follicles by follicular dendritic cells (FDC) that express the ligand chemokine 
CXCL13
20
. There B-cells encounter, by means of their BCR, foreign peptide antigens either 
in a soluble form (antigens under 70kDa) or bound on the membranes of antigen-presenting 
cells (macrophages, T-cells, dendritic cells)
21
. Then BCR-antigen complexes are internalized, 
Figure 3. Germinal centers consist of two functional compartments: the dark zone and the light zone. In 
the dark zone B-cells (centroblasts) undergo intense proliferation and somatic hypermutation. Then they 
migrate as centrocytes to the light zone, where affinity of the B-cell receptor is tested and class switch 
recombination occurs. B-cells can recycle multiple times between dark and light zones until enough 
receptor specificity is achieved. Besides B-cells, follicular dendritic cells and follicular helper T-cells are 
essential for the germinal center reaction. Adapted from ref
28
. 
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processed and displayed on a major histocompatibility complex (MHC) class II (MHC-II) 
molecule on the surface of the B-cell. Following antigen recognition by BCR, a specific 
chemokine receptor CCR7 is upregulated, which guides B-cells outside the follicle to a T 
zone where T cells express the CCR7 ligands CCL19 and CCL21. There the MHC-bound 
antigen is recognized by a specific T-cell receptor (TCR) and bidirectional activation between 
the respective B- and T-cells takes place
22,23
. Crucial for B-cell activation is the contact 
between the CD40 receptor on the B-cell with its ligand CD154, which is membrane-bound 
on the surface of the T-cell
24
. This contact provides strong activation and proliferation signals 
for the B-cell. Mice with disabled interaction between CD40 and CD154 do not develop 
GC
25
. This effect is also manifested in humans because mutations in CD154 lead to abolished 
CD40 signaling and X chromosome-linked immunodeficiency with so called hyper-IgM 
syndrome
26,27
. Additional stimulation for B-cells is achieved via secretion of IL-2, IL-4 and 
IL-5 by activated T-cells. T-cell-dependent activation, according to the favored hypothesis
28
, 
is competitive: only limited numbers of CD4+ T-cells are available in the parafollicular space 
and only those B-cells that display relatively strong affinity towards the antigen, and 
consequently display more MHC-II-antigen complexes, are allowed to enter follicles and 
form GC. Other B-cells, whose BCR binds the respective antigen with low affinity undergo 
alternative destinies, e.g. apoptosis due to low BCR signal and lack of T-cell stimulation
29
 or 
differentiation into GC independent long-lived (extrafollicularly/parafollicularly activated and 
maturated) plasma cells secreting low-specificity IgM antibodies
30
. 
Following activation, B-cell transform into centroblasts, migrate to the center of the follicle, 
and start fast proliferation. The duration of centroblasts’ cell cycle range between 6 and 12 
hours and they are therefore the fastest proliferating human cells
22,31,32
. Centroblasts 
uniformly have a low cytoplasm-to-nucleus ratio, therefore the area where they are located 
appears darker under a light microscope and was termed the dark zone (DZ) of GC
19
. 
Centroblasts are maintained in the DZ due to their relatively high levels of CXCR4. This 
chemokine receptor is activated by its ligand CXCL12 expressed by locally present stromal 
cells
33
. Prior to the formation of GC, the centers of follicles are mostly occupied by 
recirculating naïve B-cells. Intensely proliferating centroblasts push them out to the periphery 
of the follicle where they form a compartment called B-cell mantle
22
. 
Additionally to intense proliferation, GC is the site of a process called somatic hypermutation 
(SHM). During SHM the Ig variable region (IgV) of the rearranged IG genes is modified
34
. 
This process is heavily dependent on the activity of an enzyme called activation-induced 
deaminase (AID), which performs targeted deamination of deoxycytidine
35
. Deamination 
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leads to a formation of a U:G mispair. The type of lesion introduced to the DNA strand 
following deamination largely depends on the way in which the mispair is identified, 
processed and resolved
36
. One major pathway is the mutation recognition by the DNA base 
excision repair machinery. Then the uracil base is excised by uracil-DNA-glycosylase (UNG) 
and the abasic site is filled randomly with one of the four possible DNA bases leading to a 
potential transition or transversion
37
. Alternatively, U:G mismatch can be processed by DNA 
mismatch repair mechanism involving the mismatch repair enzymes MutS protein homolog 2 
(MSH2) and MSH6. As a result of this pathway A:T pairs in place of C:G are formed
38
. SHM 
introduce DNA lesions at approximate rate of 10
-3
 mutations per base per generation. SHM is 
related to DNA strand breaks and the majority of alterations produced are point mutations
39
. 
However, duplications and deletions were also reported
40
. Most mutations are concentrated to 
the complementarity-determining regions (CDR) of IgV as well as on coding and regulatory 
regions 2kb downstream of the transcription initiation site (Figure 4)
36
. 
Following several rounds of proliferation and SHM, centroblasts leave the DZ of the GC and 
migrate to the light zone (LZ) composed of B-cells called centrocytes in a dense mesh of 
FDC
28
. This migration is enabled by the increased expression of a chemokine receptor 
CXCR5 by DZ B-cells, which then guides them towards LZ where the concentration of 
CXCL13 is higher.
33
. Transition of centroblast to centrocytes is marked by upregulation of 
Figure 4. Localization of somatic hypermutation in the immunoglobulin gene (IG). DNA lesions are 
concentrated to complementarity determining regions within the variable sequences as well as in the 
switch regions of the heavy chains. C – constant region; CDR – complementarity determining region; S – 
switch sequences; Adapted from ref
36
. 
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CD83 and CD86 levels. These two markers are used to distinguish these two cell types in 
FACS experiments
41
. Centrocytes test the effects of recent mutagenesis in the DZ by binding 
the antigen presented on the immune complexes of the FDC. This interaction is not 
competitive, meaning that potentially every B-cell that make its way to the LZ interacts with 
FDC
42
. If the BCR of that cell has lost its affinity due to SHM, the cell undergoes apoptosis, 
due to lack of survival signals from the BCR. If BCR recognizes the respective antigen, it is 
again internalized into the B-cell, processed and displayed on the plasma membrane with a 
MHCII molecule. Similar to the initial activation, B-cells then competitively seek contact 
with T-cells for signals determining their further fate. T-cells are able to discriminate B-cells 
according to the amount of MHCII-antigen complexes presented, favoring those, which 
display more
43,44
. This, combined with the limited counts of T-cells in the LZ, proves that B-
cells have to compete for T-cell interaction. 
It has been shown that affinity maturation in GC in not a one-way process. The fraction of 
centrocytes that show strong but insufficient affinity for antigen migrate back to the DZ to 
undergo additional rounds of SHM and proliferation. This migratory pattern is termed cyclic 
re-entry
45
. 
Additionally, the LZ is thought to be the main site of class (isotype) switch recombination 
(CSR). The mechanism of CSR is relatively well known. Here as in SHM, an important role 
is played by AID, which helps to induce double stranded DNA breaks within donor and 
acceptor switch domains
46
. The DNA between these breaks is removed and the resulting ends 
are ligated by non-homologous end joining
15,47
. Naïve B-cells have potential to switch to any 
isotype and to change their antibody-coding heavy chain form µ to either ε, α or γ. Induction 
of CSR can be T-cell-dependent and independent. Besides the major role of CD40 in 
induction
48
, signaling by BAFF-R, cyclophylin-ligand interactor (TACI) and inducible T-cell 
co-stimulator (ICOS) has also been demonstrated
49,50
. The combination of cytokines and 
costimulatory signals determine the class of the resulting Ig after switching. For example 
stimulation by interferon gamma (INF-γ) results in production of IgG, while IL-4 induces 
switching to IgE. Anatomical sites also matter: B-cells located in mucosal tissues switch 
predominantly to IgA, which is most effective against microbes attempting to penetrate 
through epithelia. Different classes of antibodies have distinct effector functions and are 
involved in defense against different types of infectious agents. Therefore, CSR is an 
important step in diversification of B-cell antibody repertoire.  
After centrocytes complete BCR affinity maturation and class switching, they migrate outside 
the LZ and differentiate either into plasma cells or into memory B-cells. As will be explained 
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later, processes in the GC are prone to errors and can generate significant numbers of DNA 
lesions affecting tumor suppressors and oncogenes. These GC reaction-specific lesions 
contribute significantly to pathogenesis of B-cell lymphomas. 
 
Regulatory networks of germinal center reaction. 
Initiation of the GC, transit between functional zones, exit and differentiation are regulated by 
a complex intracellular and humoral signaling systems. Major players in these processes have 
been identified and include PAX5, BCL-6, NF-B, C-MYC and BLIMP1 (Figure 5). The 
knowledge about the precise mechanism of action is lacking for some of these molecules, but 
their role has been proven by functional experiments in vivo and in vitro
51,52
. 
BCL-6 is acknowledged as one of the most important 
transcriptional regulators of the GC reaction. Its 
expression is initiated by successful B-cell activation, 
as well as by the activity of interferon-regulatory 
factor 8 (IRF8) and MEF2B. Upon activation, BCL-6 
can bind its own promoter to negatively regulate its 
transcriptional levels
53
. Primarily BCL-6 acts as 
transcriptional repressor. It binds specific DNA motifs 
and recruits histone deacetylases (HDAC) directly or 
through interactions with other co-factors. HDAC 
deacetylate histones in target loci to render them 
inaccessible for DNA transcription. BCL-6 is strongly 
expressed in centroblasts and, to a lesser extent, in 
centrocytes. It has multiple roles in the GC reaction. 
First, it provides tolerance to the high level of DNA 
damage occurring in centroblasts and centrocytes 
during SHM and CSR, respectively. It has been shown 
that BCL-6 represses transcription of TP53 and CDKN1A and rescues cells from apoptosis 
and cell cycle arrest
54,55
. Second, BCL-6 prevents premature B-cell activation by T-cells by 
downregulating STAT1, CD69 and CD80
56,57
. This mechanism ensures that B-cells do not 
leave GC too early when sufficient BCR affinity is not yet achieved. Third, BCL-6 inhibits 
premature differentiation of GC B-cells into plasma cells, by repressing PRDM1, encoding a 
master regulator of plasma cell differentiation BLIMP1, and IRF4
58,59
. Fourth, it induces the 
expression of AID by inhibiting expression of two microRNAs, miR-155 and miR-361, which 
Figure 5. Inhibition of BCL-6 and 
plasma cell differentiation. BCL-6 is 
downregulated in centrocytes following 
activating contact with helper T-cells, 
which is transduced via NF-B and 
BCR signaling as well as protein 
acetylation. Repression of BCL-6 lifts 
the inhibition of BLIMP1 and leads to 
plasma cell differentiation. Adapted 
from
34
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negatively regulate AID
60
. BCL-6 is downregulated following strong and definitive T-cell-
dependent B-cell activation in the LZ. This permits differentiation of centrocytes into 
plasmablasts or memory-B cells
61
. Adding to its importance, BCL-6 also acts as regulator of 
transcriptional program in GC T-cells
62
. 
IRF8 is expressed in centroblasts but not in centrocytes during the GC reaction. It positively 
regulates BCL-6 and AID
63
. Furthermore, it binds PU.1 to maintain the expression of PAX5. 
Knock-out of both IRF8 and PU.1 leads to premature plasma cell differentiation in the GC
64
. 
C-MYC is upregulated for a short period during GC initiation. Later its expression is 
transcriptionally suppressed in the DZ by BCL-6 but reactivated again in the small subset of 
centrocytes in the light zone that eventually re-enter the DZ
65
. The exact effects of MYC 
activation in the GC are not clear but it is believed that it stimulates metabolism, DNA 
replication and telomerase function
66
. 
NF-κB signaling is absent in centroblasts but it is indirectly activated in centrocytes following 
strong stimulation by BCR, CD40, BAFF and cytokines and signaling by MAPK, PI3K and 
toll-like receptors
51
. Besides other important effects, NF-B activates IRF4 (MUM1p) to 
promote plasma cell differentiation
67
. 
PAX5 is a crucial transcription factor for B-cell identity maintenance. Its expression starts 
early in B-cell development upon the definite commitment of precursors to the lymphoid 
lineage at the pro-B stage, and continues throughout the mature B-cell phase as well as during 
the GC reaction. It binds a plethora of DNA sites and acts as both initiator and repressor of 
transcription. It regulates the expression of BCR components (IGH, CD79A), and other 
molecules that define B-cell identity (CD19, CD21, BLK, IRF4, IRF8)
5
. It also represses 
lineage-inappropriate markers such as FLT3, CD28, NOTCH1 and others
8
. Downregulation 
of PAX5 is essential for centrocyte differentiation into Ig-secreting plasma cell. On the other 
hand, its expression is maintained in memory B-cells
34
.  
IRF4 is expressed at low levels during GC initiation where it induces the expression of BCL-6 
and AID. During the late stages of GC reaction IRF4 is strongly upregulated in centrocytes 
following elevated BCR signaling and activation of NF-B. Then it represses BCL-6 and 
stimulates the expression of BLIMP1
52,64
.  
BLIMP1, coded by PRDM1, is essential for differentiation of B-cell into a plasma cell and its 
expression is restricted to the latter cell type. It is activated by IRF4 in late GC. During 
commitment to plasma cell, BLIMP1 represses PAX5, BCL-6 and C-MYC, which are 
responsible for B-cell and especially for B-cell GC phenotype. It also activates XPB1, which 
is important, but not essential regulator of plasma cell differentiation
68
. XPB1 induces the 
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development of the endoplasmic reticulum and accommodates cells for secretion of large 
quantities of proteins
69
. 
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1.2 Diffuse large B-cell lymphoma, not otherwise specified (NOS)  
Diffuse large B cell lymphoma (DLBCL) is an aggressive form of B-cell lymphoma, which 
accounts for 30% of all newly diagnosed lymphomas worldwide
70
. The median age of 
occurrence is between 60 and 70 years, but it can also arise in young adults and children. 
DLBCL is slightly more frequent in males than in females
71,72
. It can affect nodal and 
extranodal sites. The most frequent extranodal locations are the gastrointestinal tract, the 
bones, testes, spleen and Waldeyer’s ring. Predominantly DLBCL is a de novo disease, but it 
can also manifest as transformations from other more indolent lymphoid neoplasms such as 
follicular lymphomas, marginal zone lymphomas and chronic lymphocytic leukemias (the 
latter is called Richter’s transformation). DLBCL is a very heterogeneous disease, which has 
distinct morphological, phenotypic, molecular and clinical characteristics. Some of those 
characteristics have been used as a basis for a numerous different classifications (see Table 
1)
72
. 
Table 1. Categorization of DLBC in the 4
th
 edition of WHO classification of hematopoietic and lymphoid 
tissues
72
. ALK, anaplastic lymphoma receptor kinase; CNS, central nervous system; EBV, Epstein-Barr 
virus; HHV8 human herpes virus 8. 
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Gene expression and genetic studies revealed several molecular subtypes of DLBCL: the 
germinal-center B-cell (GCB) subtype, the activated B-cell (ABC) subtype and the primary 
mediastinal large B-cell lymphoma (PMBCL) subtype
73–75
. However, 10-15% of DLBCL 
cases cannot be classified into any of these categories. The three DLBCL subtypes are thought 
to derive from distinct B-cell developmental phases as their gene expression profiles match 
closely with the gene expression profiles of their healthy counterparts. Thus, the cell of origin 
(COO) concept has emerged. It has been shown that gene expression profile of GCB-DLBCL 
closely matches with a profile of healthy GC B-cells. Moreover, GCB-DLBCL frequently 
express BCL-6, CD10, GCET1, HGAL and LMO2 and have highly mutated IG genes, which 
are all properties of GC B-cells. In contrast, the transcriptional signature of ABC-DLBCL 
matches best with the one of post-GC B-cells or plasmablasts; they more frequently express 
IRF4, FoxP1, CD44 and lack CD10 as well as GCET1. PMBCL originates from a rare thymic 
B-cell and is morphologically (clear cells, compartmentalizing fibrosis), phenotypically 
(CD23+, CD30+, p63+), molecularly (JAK2 and PDL1 locus gains, C-REL locus gains, 
PTPN1, STAT6 and SOCS1 mutations) and clinically clearly distinguishable from the other 
two subtypes.  
Some authors argue that the COO concept can be misleading, because it gives an impression 
that lymphomagenesis start at a defined stated phase of B-cell development. In reality, 
however, the actual initiating events could potentially occur at an earlier stage of B-cell 
development, but allow further development up until the stage where additional genetic 
aberrations impose a differentiation block. Thus, COO would represent not the actual normal 
counterpart, but the stage at which differentiation block occurred
76
. Several findings support 
this line of reasoning. For example, the t(14;18) translocation involving the BCL2 oncogene 
and the IGH gene is clearly a pathogenic event and is frequently found in GCB type of 
DLBCL. However, it is known that this translocation occurs due to aberrant V(D)J 
rearrangement during the pre-B phase of B-cell development - a far earlier stage than a GC 
centroblast, which is the hypothesized normal counterpart of GCB-DLBCL
77
. Additionally, it 
is known that malignant cells of ABC type of DLBCL most frequently express IgM
78
. Again, 
this is contradictory to a suggested understanding that ABC-DLBCL develop from post-GC 
plasmablast, since isotype switch occurs in the light zone centrocytes prior to plasmacytic 
differentiation
79
.  
Although COO classification was produced by genome-wide gene expression profiling, 
numerous additional techniques were shown to closely reproduce the initial findings. These 
include immunohistochemical and transcriptional profiling algorithms of a selected subset of 
markers, classification according to Ig expression and others
80–83
. These approaches not only 
INTRODUCTION 
 
17 
 
replicated the results of COO classification by assigning DLBCL cases to the same subtype, 
but also showed that the distinguished categories differ in many additional aspects and thus 
proved the relevance of the initial findings. These endeavors were mainly pursued due to 
notion that COO classification has not only biological but also prognostic
74,84
 and 
therapeutic
85,86
 significance. There was and still is a need of a quick, robust but simple method 
to reliably classify new DLBCL cases. 
 
1.2.1 Molecular pathogenesis of DLBCL 
As all cancers, DLBCL is an uncontrolled accumulation of cells due to numerous genetic 
lesions – amplifications, deletions, translocations and point mutations – that change cell’s 
regulatory circuits either by activating pro-oncogenic pathways or by inactivating 
mechanisms that keep cell’s growth in check. In addition to common oncogenic processes, 
DLBCL employ B-cell-specific physiological mechanisms to generate additional lesions. It 
has been proven that aberrant somatic hypermutation (ASHM), defects in RAG1/2-mediated 
IG rearrangement and error-prone CSR can cause additional lymphoma-specific lesions
87–89
. 
These lesions are even more likely because cells have an increased tolerance to DNA damage 
and higher threshold for apoptosis throughout a GC reaction
54
.  
During the last five years revolutionary DNA sequencing technologies allowed sequencing of 
several hundred full DLBCL genomes or exomes
90–93
. These sequencing studies have 
confirmed some previously known mutations in established drivers of lymphomagenesis, but, 
more importantly, identified new recurrent mutations in genes, whose role in DLBCL was not 
yet recognized. Coupled with functional studies on many of these newly identified genes, a 
more comprehensive picture of the genetic landscape of DLBCL has emerged. Despite rather 
complex genomes and relatively high mutational rate (on average 50-100 DNA lesions per 
genome), most of mutations converge on several cellular pathways indicating their key role in 
lymphomagenesis
76
. Some of these pathways are common for all subtypes of DLBCL 
showing their common origin from a developing B-cell. Others are characteristic only to one 
particular subtype in accordance to differences in molecular classification and clinical 
characteristics (Figure 6). 
 
Alterations common for all subtypes 
At least three different cellular processes were found to be consistently affected in all 
subtypes of DLBCL. These include epigenetic maintenance of normal chromatin state, 
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regulation of BCL-6 transcription and cell control by the immune system. Mechanisms of 
deregulation are ambiguous as multiple components of the same pathway can be deregulated 
resulting in same or similar outcome. 
 
Genetic lesions in chromatin modifiers 
CREBBP, EP300 and KMT2D are the most frequently mutated genes in all subtypes of 
DLBCL that affect chromatin remodeling
94
. CREBBP and EP300 are two acetyltransferases 
that acetylate both histone and non-histone protein residues and in this way alter the activity 
of numerous DNA-binding transcription factors. They are mutated in approximately 40% of 
DLBCL
95,96
. Predominantly, all these mutations are inactivating, but occur only in one of the 
two alleles, suggesting that the function of these proteins is dose-dependent. It has been 
shown, that lack of function of both CREBBP and EP300 impairs acetylation of BCL-6 and 
TP53 and disrupts their normal functions.  
KMT2D codes for a methyltransferase that methylates lysine at the 4
th
 position of histone 3 
(H3K4). It is mutated in at least 30% of DLBCL. Most of mutations are inactivating, and 
present in both alleles, suggesting the importance of total KMT2D loss for lymphomagenesis. 
Figure 6. Genetic lesions in DLBCL. Germinal center reaction and its relation to different subtypes of 
DLBCL pathogenesis is schematically represented. Below, the most frequent genetic alterations are 
shown with nearby squares color-coded according to the affected cellular process. Blue - loss of 
function; red - gain of function. FDC – follicular dendritic cell. Adapted from 94  
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Despite high mutational frequency, the precise effects of KMT2D abrogation are currently 
unknown. Animal experiments showed diminished global H3K4 methylation in GC cells and 
increase of GC B-cell count. Moreover, ablation of Kmt2d in mice that overexpress Bcl-2 led 
to increased incidence of GC-derived lymphoma. It is therefore suggested that KMT2D acts 
as a tumor suppressor. Its early loss might promote lymphomagenesis by modification of the 
broad epigenetic landscape of the cancer precursor B-cells
97
.  
 
Deregulation of BCL-6 
The lymphomagenic potential of BCL-6 deregulation has been demonstrated in mouse 
models
98
. Constantly active BCL-6 renders cells resistant to apoptosis, tolerant to a genetic 
stress and blocks further differentiation by stable inhibition of PRDM1
61
. Approximately 50% 
of DLBCL, more frequently ABC-DLBCL, have direct or indirect deregulation of this 
oncogene. One of the best described mechanism of direct deregulation are translocations 
(observable in 30% of DLBCL, 25% GCB-DLBCL, 40% ABC-DLBCL), which put the intact 
coding part of BCL-6 under the control of differentially regulated promoters. In such case 
BCL-6 looses its normal transcriptional regulation and is not silenced at the end of the GC 
reaction
99. Additionally, the 5’ end of BCL-6 is recurrently affected by point mutations, 
which, most likely, are the result of an ASHM. These lesions can have a double effect: first, 
they might disrupt auto-regulatory mechanisms of BCL-6 by which it can downregulate its 
own expression
53
; second, they can impair binding of IRF4, which normally repress BCL-6 
following activation by CD40 
100
. Indirectly, BCL-6 is deregulated by decreased activity of 
EP300 and CREBBP. Furthermore, 10-15% of DLBCL harbor activating mutations in the 
MEF2B transcription factor - a positive regulator of BCL-6. Finally, 4% of DLBCL cases 
have loss-of-function mutations/deletions of FBXO11 that impair proteosomal degradation of 
the BCL-6 protein
61
.  
 
Immune escape 
More than 60% of DLBCL lack expression of MHC class I (MHCI) molecules on the cell 
surface. Lacking MHCI, lymphoma cells are “invisible” for both cytotoxic T-lymphocyte- and 
natural killer cell-mediated immune surveillance. In about 30% of cases this defect is 
attributed to disruptive mutations of the B2M gene, which codes for beta-2-microglobulin - a 
key subunit of MHCI complexes
90
. Additionally, MHCI expression can be lost due to either 
frequent deletions of the HLA-A, HLA-B and HLA-C loci, which are especially frequent in 
DLBCL of the central nervous system, or by defect transport of the B2M protein to the cell 
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surface. In 21% of cases loss-of-function mutations affect the CD58 gene, which encodes a 
protein necessary for natural killer- and T-cell-mediated cell responses
101
.  
Other genes that are frequently affected in all types of DLBCL are TP53 and FOXO1. FOXO1 
is a transcription factor that act as a tumor suppressor downstream of PI3K/AKT signaling 
pathway. About 9% of DLBCL bear mutations in the 5’ end of the FOXO1 gene. They 
deregulate its translocation to the nucleus and binding to its transcriptional targets
102
. These 
mutations are likely to occur due to ASHM. The TP53 gene is directly inactivated by 
damaging point mutations/deletions in about 25% of DLBCL, abolishing its anti-tumor 
activities
91,103
. 
 
Lesions associated with GCB-DLBCL 
Best characterized GCB-DLBCL-specific genetic aberrations are chromosomal translocations 
involving C-MYC (most frequently t(8;14)) and BCL-2 (most frequently t(14;18)). They are 
detected in ~10 and ~30% of GCB-DLBCL, respectively and result in elevated expression of 
the involved proteins. These lesions are thought to at least partially override the BCL-6-
mediated suppression of C-MYC and BCL-2, to promote cellular growth and grant resistance 
to apoptosis
104,105
. 
Recently, the histone methyltransferase EZH2 was associated with GCB-DLBCL 
pathogenesis. A gain-of-function EZH2 mutation targeting the Y641(N) hotspot was detected 
in ~20% of cases
106
. Normally, EZH2 effectively converts unmethylated lysine 27 of histone 
Figure 7. Schematic representation of events involved in GCB-DLBCL pathogenesis. Adapted from
51
. 
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3 (H3K27) to a mono-methylated state. Mutations in EZH2 change this efficiency and 
increase the conversion of K27 to a tri-methylated state
107
. Tri-methylated lysine residue 
represses transcription of targeted DNA regions. Among targets of aberrant EZH2-mediated 
transcriptional repression are PRDM1, IRF4 and CDKN1A. In mouse model hypermethylation 
of H3K27 results in B-cell differentiation blockade, GC hyperplasia and lymphomagenesis
108
.  
Around 30% of GCB-DLBCL have a disrupted Gα13 pathway that is responsible for growth 
and localization of GC B-cells. This disruption is associated with mutations in sphingosine-1-
phosphate receptor-2 (S1PR2), guanine nucleotide binding protein alpha 13 (GNA13), RHO 
guanine nucleotide exchange factor 1 (ARHGEF1) and purinergic receptor P2Y (P2RY8)
109
. 
Normally GC B-cells remain strictly within the lymphoid organs and do not recirculate. 
Mutations in GNA13 and ARHGEF1 cause dissemination of GC B-cells to lymph fluid and 
blood. This effect was not achieved by S1PR2 mutations. However, S1PR2 alterations led to 
GC-type lymphoma formation in mice
110
. Taken together, these findings reveal a mechanism 
by which lymphoma cells can leave their tissue of origin and spread to distant sites. 
Amplification and overexpression of miR-17-92 occurs in 12.5% of GCB-DLBCL
111
. The 
expression of this microRNA is controlled by a complex transcriptional network containing 
oncogenes and tumor suppressors. Its upregulation is caused by a coordinated activity of 
transcription factors C-MYC and E2F
112
. On the other hand it is downregulated by p53 under 
hypoxic conditions
113
. The active transcription of miR-17-92 is thought to downregulate 
PTEN, CDKN1A and BIM, which allows tumor cells to escape senescence and to grow more 
rapidly
114,115
. Mice with transgenic overexpression of miR-17-92 cluster develop 
lymphoproliferative disease
116
. In addition to silencing by miR-17-92, PTEN is lost due to 
deletions in 6 to 55% of GCB-DLBCL cases
111,117
. 
 
Genetic lesions associated with ABC-DLBCL 
Mutations detected in ABC-DLBCL are thought to promote lymphomagenesis by two main 
mechanisms: activation of NF-B transcription factor signaling and preventing of terminal 
differentiation. Additionally, specific types of BCR displayed on the surface of ABC-DLBCL 
cells contribute to their phenotype and behavior. IgM expression is atypical for post GC B-
cells, since class switch happens during the GC reaction. However, the majority of ABC-
DLBCL have a native IG heavy chain genes and therefore produce BCR that contains IgM. 
The heavy chain of IgM has a shorter intracellular domain compared to other class-switched 
Ig, such as IgG. Because of that it delivers qualitatively different signals to the cell: IgM 
provides signals associated with cellular proliferation and survival, whereas IgG produces 
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strong ERK, MAPK and calcium responses that promote B-cell differentiation into plasma 
cell
118,119
. 
Chronic signaling of NF-B 
NF-B transcriptional family consists of five family members: p65, c-Rel, RelB, p105/p50 
and p100/p52. In the resting state they are bound by their specific inhibitors and sequestered 
in the cytoplasm. Activation by an upstream signaling removes this inhibition, NF-B 
transcription factors form heterodimers and translocate to the nucleus where they elicit their 
functions by binding multiple DNA targets
120
. The activation can be achieved either via 
classical (canonical) or alternative (non-canonical) pathways. Canonical activation pathway is 
by far the most important one in the context of ABC-DLBCL
76
. NF-B signaling is 
transiently active during B-cell activation and differentiation. It controls a broad range of 
cellular processes such as immune and stress responses, apoptosis, proliferation, 
differentiation and development
120
. However, in ABC-DLBCL NF-B signaling is 
chronically active and drives lymphomagenesis by aberrant expression of cyclin D1, cyclin 
D2, BCL-2, C-MYC, IL-2, IL-6 and others
121–123
. Mice with chronic NF-B activation 
develop B-cell and plasma cell hyperplasia and additional inactivation of BLIMP1 leads to 
formation of lymphomas reminiscent of ABC-DLBCL
124
. Inhibition of NF-B signaling kills 
ABC-DLBCL cells
125
. Constitutive activation is achieved by multiple mechanisms such as 
chronic BCR signaling, MYD88 mutations (see later) and disruption of negative regulation 
circuits (Figure 8). 
 
Chronic BCR signaling  
Survival and development of B-cells is dependent on their ability to display functional BCR. 
Upon antigen encounter, BCR forms clusters in the plasma membrane bringing multiple BCR 
in a close physical proximity. This facilitates Src-family kinase-mediated phosphorylation of 
tyrosine residues on the immunoreceptor signaling motif (ITAM) domains of CD79A and 
CD79B. These phosphorylated residues provide binding sites for SH2 domains of the spleen 
tyrosine kinase (SYK). It induces a broad signaling cascade that engages the NF-B, PI3K, 
MAPK, RAS and other signaling pathways
126
.  
It is known that even in the absence of cognate antigens naïve B-cells depend on signals from 
BCR. These signals are termed tonic BCR signaling
127
. In contrast, ABC-DLBCL cells often 
have BCR clustered on the membrane surface indicative of chronic active signaling. This 
chronic signaling can potentially be attributed to BCR activation by self antigens
128
. 
Additionally, more than 20% of ABC-DLBCL cases bear mutations in the ITAM domains of 
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CD79A and CD79B. These mutations are thought to circumvent negative feedback regulation 
loops (prevention of receptor endocytosis and/or suppression of LYN kinase activity), thus 
maintaining chronically active BCR signaling. Knock-down of CD79 adaptors leads to 
apoptosis of specifically ABC-DLBCL cell lines
129
. 
In around 9% of ABC-DLBCL activation of BCR-like signaling and consequent NF-B 
activation is caused by mutations in the caspase recruitment domain-containing protein 11 
(CARD11) gene
92,130
. CARD11 is a multi-domain signaling adapter, which translocates to the 
inner side of plasma membrane upon phosphorylation by the upstream components of the 
BCR signaling pathway. It then interacts with BCL10 and MALT1 and forms a so-called 
CBM complex
131
. The active CBM complex eventually facilitates degradation of the NF-B 
inhibitor complex (IκB) and allows transcription factors to enter the nucleus. Mutations in the 
coiled-coil domain render permanent activation of CARD11 and abrogate the need of 
phosphorylation. This results in BCR-independent activation of NF-B132.  
 
Mutations of MYD88 
Approximately 30% of ABC-DLBCL patients harbor mutations in the gene encoding myeloid 
differentiation primary response protein 88 (MYD88). Although several different mutations 
have been described, the most frequent mutation cause a L265P amino acid change in the 
intracellular Toll/IL-1 receptor domain (TIR) of this adaptor molecule. This mutation allows 
MYD88 to spontaneously assemble a complex containing of IRAK4 and IRAK1, which leads 
to activation of NF-B. Mutations in MYD88 can also cause JAK/STAT3 transcriptional 
Figure 8. Schematic representation of pathways deregulated in ABC-DLBCL. Adapted from
51
. 
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responses
133,134
. Genetic and functional data shows, that MYD88 mutations cooperate with 
chronic active BCR signaling to induce NF-B and promote lymphomagenesis. These lesions 
are overlapping in a significant share of ABC-DLBCL cases. Moreover, simultaneous 
inactivation of MYD88 and CD79A results in higher toxicity for lymphoma cells than 
abrogation of any of these molecules alone
133
. 
 
Disruption of negative regulation of NF-B 
In addition to a wide range of activators, NF-B has also several repressors, which 
downregulate its transcriptional response after the physiologic goals of signaling are 
completed. These negative regulators act as tumor suppressors and are recurrently targeted by 
inactivating mutations in ABC-DLBCL. One of such regulators is a deubiquitinating enzyme 
A20 encoded by TNFAIP3 gene. It is involved in termination of toll-like receptor induced 
NF-B signaling. A20 exerts its activity by post-transcriptional modification of several 
members of NF-B pathway, targeting them for proteosomal degradation. Both alleles of 
TNFAIP3 are inactivated by truncating mutations/deletions in 30% of ABC-DLBCL cases
135
. 
These mutations cause prolonged NF-B responses leading to active proliferation and 
resistance to apoptosis. In mice, knock-down of TNFAIP3 leads to spontaneous inflammation 
and inability to terminate toll-like receptor -dependent activation of NF-B136. 
 
Blocking of plasma cell differentiation 
Blocking of differentiation in ABC-DLBCL occurs via multiple mechanisms, all of which 
eventually converge to the master regulator of plasma cell development BLIMP1. First, 
PRDM1 gene encoding BLIMP1 is lost due to bi-allelic truncating mutations/deletions in 
~25% of cases. Second, PRDM1 can be constitutively suppressed by aberrantly active BCL-6. 
Finally, it is recently discovered that ~25% of ABC-DLBCL have gain-of-function mutations 
in SPIB
111
. This gene encodes a transcription factor, which directly binds IRF4 and disrupts 
an IRF4-mediated induction of PRDM1 expression
137,138
. The profound impact of BLIMP1 to 
lymphomagenesis is demonstrated by experiments showing that mice lacking PRDM1 
develop NF-B-dependent lymphomas, reminiscent of ABC-DLBCL124,139  
  
1.2.3 Treatment of DLBCL 
DLBCL is an aggressive disease but it can be successfully treated and cured in >50% of all 
cases, even in advanced stages. Currently the treatment of choice is a multi-agent 
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chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin, oncovin and 
prednisone combined with a chimeric monoclonal antibody against the CD20 receptor, 
Rituximab (R-CHOP)
140
. Prior to introduction of Rituximab, CHOP alone was used for 
treatment. The first large clinical study comparing treatment outcomes of CHOP vs R-CHOP 
came out in 2002. It reported approximately 15% improvement in complete remission, 2-year 
event free survival (EFS) and 10-year overall survival (OS)
141
. These results were confirmed 
by additional studies on various different patient cohorts
142,143
. There have been attempts to 
develop and test additional chemotherapy regimens for treatment of DLBCL and they had 
some success. For example, a dose-adjusted treatment with etoposide, doxorubicin, 
cyclophosphamide, vincristine, prednisone and rituximab (DA-EPOCH-R) showed high 
efficiency against PMBCL
86
 and is probably more efficient in ABC-DLBCL. 
The standard salvage treatment for patients who fail to respond to the initial therapy or recur 
after a period of complete remission is high-dose chemotherapy supported with autologous 
stem cell transplantation (ASCT). However success rates are poor
144
. 
Molecular subgroups of DLBCL respond differently to standard therapy. Nearly 100% of 
PMBCL can be cured with R-CHOP or DA-EPOCH-R. In a clinical study of 69 patients with 
previously untreated DLBCL, for the group of GCB-DLBCL a 100% 5-year progression free 
survival (PFS) was reported, but for ABC-DLBCL the PFS was only 69%
145
. This shows, that 
the majority of patients who relapse, have the latter type of lymphoma. 
The recent directions of improving outcomes for DLBCL patients has been undoubtedly 
related to the plethora of new genetic information that has been acquired about this group of 
tumors during the last decade. The presumption is that if one can find out what the drivers of 
lymphomagenesis are in each individual tumor and understand the principles by which they 
promote cancer formation, selective interference with their signaling circuits can be exercised 
and the benefits that tumor cells are gaining from them can be abolished. This is the idea of 
precision medicine. To that direction, a lot of different compounds have been developed 
which interfere with nearly every driver molecule and signaling circuit described in the 
previous section (Figure 9)
140
. Many of them showed efficacy in killing DLBCL cells in vitro, 
some entered clinical trials and some have already been successfully used for treating patients 
with relapsed or refractory DLBCL.  
Arguably, the most successful of them was PCI-32765 termed ibrutinib. Ibrutinib acts upon 
and irreversibly inhibits Bruton’s tyrosine kinase (BTK) - a signaling kinase, which 
transduces signals coming from BCR to activate the NF-B pathway. It acts downstream of 
BCR, but upstream of CARD11. Consequently, ibrutinib is effective against tumors with 
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chronic BCR activation e.g. due to self-antigens or CD79A and CD79B mutations. It is 
completely inefficient against tumors with mutations in coiled-coil domain of CARD11, or 
tumors with altered MYD88
129,146
. Interestingly, ibrutinib is effective against tumors with both 
CD79B and MYD88 mutations, probably because of cooperation of these two alterations in 
lymphomagenesis
133
. In recent phase I/II clinical trial 37% of relapsed/refractory ABC-
DLBCL patients responded positively to treatment with ibrutinib showing benefits in PFS and 
OS
147
. In the same study only one patient with GCB-DLBCL responded. Ibrutinib showed a 
good tolerance and manageable side effects, so further the efficacy of this targeted treatment 
will be tested in a phase III clinical trial only on ABC-DLBCL patients
147
.  
In addition to targeted single molecule inhibitors, lenalidomide has shown some good 
potential in managing relapsed/refractory DLBCL, especially ABC-DLBCL. It is an 
immunomodulatory drug, which has a direct anti-neoplastic activity. By targeting tumor 
microenvironment it induces blocking of tumor cell proliferation and angiogenesis as well as 
stimulation of T-cell- and natural killer cell-mediated immune responses
148–150
. Lenalidomide 
Figure 9. Signaling pathways in DLCBL and compounds that are used for their inhibition. Note that one 
signaling pathway can be inhibited by multiple agents at different levels, potentially precluding the 
development of resistance. Adapted from
258
. 
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also downregulates the expression of IRF4 leading to increased IFN-β production146. Different 
regimens are being tested, ranging from lenalidomide monotherapy to its combination with 
Rituximab or even complex combinations with multiple chemotherapy agents
151
. A recent 
clinical trial reported a 30% response rate to lenalidomide treatment in refractory/resistant 
DLBCL
152
. Another study showed the predominant effect of single lenalidomide therapy 
against relapsed/refractory ABC-DLBCL. The overall response rate in this subtype was 
52.9% as compared to only 8.7% in GCB-DLBCL (p=0.006). Despite this, there was no 
difference in OS between the two subtypes
153
.  
To conclude, currently satisfactory treatment results of DLBCL are expected to improve 
following the entrance of variety of single molecule inhibitors to clinical use. In particular, 
management of relapsed/refractory DLBCL has to be improved. This can be achieved by 
identification and efficient simultaneous targeting of multiple cellular pathways (or even 
several components of the same pathway, to increase efficiency) on which the survival and 
growth of tumor cells depend.  
 
1.2.4 Prognostic and predictive markers in DLBCL 
A key requirement for a successful individualized DLBCL therapy is the availability of 
prognostic and particularly predictive biomarkers. Such biomarkers should provide reliable 
information on the likely clinical course of newly diagnosed tumors (prognostic value) as well 
as identify patients, who would profit the most from available treatments (predictive value).  
The international prognostic factor (IPI) is a prognostic factor based on biological and clinical 
parameters, such as age, stage of disease, level of serum lactate dehydrogenase, performance 
status and sites of involvement. It was introduced in 1993 and separated DLBCL patients into 
4 distinct groups, which had a 5-year OS ranging from 26 to 73%
154
. The IPI was revised after 
introduction of Rituximab to therapy regimens. Although it maintained its prognostic value, 
the range of outcomes narrowed substantially, and the high-risk patients cannot be identified 
reliably
155,156
. Besides IPI other clinical prognostic factors have been proposed. They include 
tumor size, gender, presence of tumor involvement of the bone marrow, serum level of free 
chains and others
157–160
. 
The molecular classification of DLBCL by gene expression profiling also has a prognostic 
value. The 3-year PFS is lower in ABC-DLBCL compared to GCB-DLBCL (40% vs 75%, 
p<0.001)
84
. However, gene expression profiling of fresh or fresh-frozen tumors by 
microarrays is not practical in diagnostic setting because it requires fresh or fresh-frozen 
tumor material, lengthy and time consuming laboratory procedures. Therefore, 
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immunohistochemical algorithms as well as alternative methods for transcriptional profiling 
of subset of genes were developed, which allow satisfactory allocation of DLBCL cases to 
either of molecular subtypes
82,83
. In addition to its prognostic value, molecular subtyping also 
provides information about likely genetic alterations that drive tumor formation. This 
information can be used to target aberrant cellular circuits in a personalized manner. 
The presence of concurrent translocations of C-MYC and BCL-2 is one of the strongest 
negative prognostic markers in DLBCL. Such tumors are termed “double-hit” lymphomas and 
have an extremely poor outcome with median survival of approximately 8 months when 
treated with standard R-CHOP therapy
161
. This suggests that all new patients who are 
diagnosed with DLBCL containing both of these genetic lesions should be treated with more 
aggressive alternative regimens
161
. Although translocations of BCL-2 and C-MYC often lead 
to protein overexpression, detection by genetic rather than immunohistochemical methods is 
preffered
162
.  
Similarly to clinical markers, evaluation of prognostic and predictive biomarkers by 
immunohistochemistry (IHC) is technologically and economically feasible. Additionally, 
inherent to this technology is that it measures the amount of protein, which is an end product 
and a potential determinant of oncogenic effects. This is not the case in, for example, 
transcriptional profiling. Therefore the use of many IHC-based biomarkers was proposed. 
Most important ones include such molecules as MUM1p, BCL-2, BCL-6, FOXP1, C-MYC, 
CD10 and CD5. They can be used either as single markers or in combinations attempting to 
create a functional prognostic model
163–166
. However, IHC suffers from relatively poor 
reproducibility, which is dependent on the use of different procedures, inconsistent cut-offs 
and subjective scoring. There has been efforts to reduce these drawbacks and to standardize 
IHC marker evaluation
167,168
.  
The positron emission tomography with computed tomography imaging (PET/CT) is 
routinely used to locate sites of lymphoma involvement at DLBCL diagnosis. It has also been 
shown that the presence of identifiable tumor masses at the end of the standard treatment is 
associated with worse PFS and OS. A consolidation radiotherapy is suggested for such 
patients to increase chances of sustainable remissions
169,170
. 
Most DLBCL relapses occur within two years after initial diagnosis. Event-free status of 
minimum 24 months after the initial diagnosis is regarded as one of the strongest predictors of 
a long term survival. Patients, who do not have a relapse during the next two years following 
diagnosis have and excellent prognosis with OS similar to that of age- and sex- matched 
general population
171
.  
Currently no effective predictive markers in DLBCL are available. One potential candidate is 
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the presence of MYD88 gene mutations, which predict a poor response to ibrutinib in 
relapsed/refractory DLBCL. However, it is not yet a standard treatment. Additionally, 
molecular subtype seems to predict treatment efficacy of bortezomib and ibrutinib as both are 
more potent against ABC-DLBCL
86
.  
 
1.2.5 Clinical importance and biological background of DLBCL relapses 
Current treatment options provide favorable outcomes to large part of DLBCL patients who 
either enter a long-time clinical remission or are cured. However, ~30% of patients who fail 
the initial therapy either because of resistance to the treatment (~10%) or due to especially 
early relapse (~20%) have a dismal prognosis and often succumb to disease
143,172
. Moreover, 
the addition of Rituximab to a first-line regimen, yet bringing a high advantage to the long 
term outcome of all DLBCL patients, resulted in significantly inferior outcomes after 
secondary treatment
173
 As mentioned earlier, the treatment of choice for such patients are 
more aggressive chemotherapy regimens and ASCT
174
. However, this treatment is associated 
with risks of lethal infections and severe toxicity. Only ~50% of patients can sustain such an 
intense approach; others are not eligible due to advanced age or comorbidities. 
Besides double rearrangements of BCL-2 and MYC there are no reliable prognostic markers to 
identify patients with unfavorable outcome
171
. Even the high-risk category identified by IPI 
has ~50% chance of cure and provides no rationale for deviating from the standard first line 
R-CHOP treatment. Therefore, refractory/relapsed DLBCL present a yet unmet challenge in 
terms of understanding the underlying biological mechanisms, identifying prognostic markers 
that would identify these patients before starting treatment and, most importantly, developing 
effective treatments capable of curing more patients. 
The majority of recurrences happen during the first 3 years after initial therapy. However, 
~10% of patients relapse >5 years after the first diagnosis. It is hypothesized, that 
resistance/relapse occurs either due to intrinsic tumor heterogeneity or as a consequence of 
ongoing genomic tumor evolution under the selective pressure of therapy, or both. Initial 
genetic heterogeneity of the tumor can confer propensity to relapse due to present subclonal 
population(s), which have a pre-developed resistance to treatment and which can outgrow 
following extermination of the dominant clone
175
. On the other hand, genomic tumor 
evolution can occur after treatment if the initial clone was not completely eradicated. This 
evolution can potentially be driven by genetic instability caused by DNA alkylating and 
intercalating agents present in the chemotherapy regimen (cyclophosphamide and 
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hydroxydaunorubicine in CHOP) and consolidated by selective pressures exerted by the 
treatment like immunosuppression/immune escape
176
. 
The genetic and biological mechanisms of therapy resistance and relapses are just started to 
be uncovered. Up to date as little as 3 dedicated studies have addressed the genetic 
background of DLBCL relapses
175,177,178
. All three studies combined, 66 exomes of 
relapsed/refractory DLBCL were analyzed, among them there were 7 matched primary-
relapse pairs. The remaining samples were either single refractory/relapse cases or matched 
relapse/normal pairs. Each study reported somewhat different results concerning potential 
drivers of DLBCL relapse. This can be attributed to relatively small study cohorts, which are 
far from saturating and comprehensively representing the full spectrum of such a 
heterogeneous disease like DLBCL. Direct comparison of matched diagnostic and relapse 
samples provides several advantages: first, it allows studying only genetic alterations that 
occurred specifically at relapse; second, it allows identification of patient-specific shared 
somatic mutations, which represent early drivers in tumorigenesis; third, it allows 
investigating tumor evolution at a genome scale. 
Deep-sequencing of IGH rearrangements in 14 primary-relapse pairs identified two patterns 
of tumor evolution: 1) in an early-divergent pattern, IGH locus of primary and relapse tumors 
had the same V(D)J rearrangement but significant differences in the SHM profiles; they 
clustered into two distinct groups indicating that populations bearing those rearrangements 
separated early and evolved independently; 2) in a late-divergent pattern, IGH sequences 
clustered to the same group as there were minimal differences in the SHM profiles; this 
suggests that these tumors separated late and didn’t acquire many tumor-specific alterations. 
Similar evolution patterns were also discovered in DLBCL that arose as transformation from a 
follicular lymphoma
179,180
.  
In search of possible genetic drivers of relapse, several commonly mutated genes and 
pathways were identified. Jiang et al. suggested that DLBCL relapses might be driven by 
mutations in immune surveillance genes. Exome-sequencing revealed relapse-specific 
alterations in either CD58 or B2M or both in 5 out of 7 investigated pairs
175
. Another study 
reported B2M and CD58 mutations enriched in relapses of PMBCL-DLBCL and ABC-
DLBCL, respectively
177
.  
Alterations in the JAK-STAT pathway components were also reported. STAT6 bore mutations 
of D419 residue in ~40% of relapsed/refractory DLBCL. Mutational status correlated well 
with the expression of phosphorylated STAT6 levels in affected tumors, indicating, that these 
lesions were activating
178
. Additionally, inactivating mutations in SOCS1, a negative regulator 
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of JAK-STAT pathway, were also frequently detected, predominantly in PMBCL subtype of 
DLBCL
177
. 
Alterations in NFKBIE and NFKBIZ have not previously been reported in the context of de 
novo DLBCL pathogenesis. These two genes encode IκBε and IκBζ, respectively - two 
inhibitors of NF-B pathway. They were mutated at a combined frequency of 18% within the 
studied relapsed/refractory DLBCL cohort
178
. Given the important role of NF-B pathway in 
lymphomagenesis, it is likely that these mutations could provide an alternative NF-B 
activation mechanism for tumor cells
181
. 
In some cases relapse-specific alterations could be detected at a very low frequency in 
diagnostic DLBCL biopsies, suggesting the presence of minor therapy-resistant clone in the 
primary tumor. Selection at relapse was observed by increased allelic frequency of the 
mutation. However, these findings were not confirmed by all reports so remains controversial. 
Other frequently reported genes in these studies included TP53, KMT2D, PIM, MLL3, EZH2, 
FOXO1, MYD88, CCND3, FAS, FOXP1, GNA13, CARD11 and others. However, due to 
inherent limitations (lack of paired primary-relapse samples), the relapse-specific nature of 
theses mutations is uncertain, especially given the fact that many of them are known to be 
related with the molecular pathogenesis of de novo DLBCL.  
 
1.2.6 Clonal relationship in relapsing lymphomas 
Second and subsequent occurrences of lymphoid neoplasms in the same patient after a period 
of complete remission are traditionally regarded as clonally-related outgrowths of the primary 
tumor. Since an acquired tumor resistance is expected, more aggressive second line treatment 
strategies are applied in such instances. However, the concept of clonally-related relapses has 
been challenged by multiple studies, showing that a significant percentage of secondary 
occurrences represent a second clonally unrelated neoplasm. 
In the biggest published study on DLBCL clonality so far, 13 pairs of DLBCL relapsing 4 
years or later after initial diagnosis were investigated. Authors reported 3 cases (23%) in 
which clonal relationship could not be confirmed. However, the methodology employed did 
not allow unambiguous demonstration of lack of clonal relationship either
182
. In a smaller 
study all 5 (100%) DLBCL relapses, which localized to the central nervous system, were 
found to be unrelated to the initial tumors (4 DLBCL, 1 mantle cell lymphoma)
183
. The most 
recent report found 2(20%) clonally-unrelated relapses within the paired cohort of 10 DLBCL 
cases
184
. 
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Lack of clonal relationship has also been associated with morphological transformations of 
more indolent lymphoid neoplasms. For example ~22% of DLBCL relapses emerging as 
Richter’s transformations had distinct IGH rearrangements185,186. Also, approximately 20% of 
classical Hodgkin lymphoma relapses represent de novo lymphoid neoplasms
187
. 
The occurrence of a second clonally-unrelated lymphoid neoplasm suggests the existence of 
risk factors, which can predispose patients to acquire a second tumor the same diagnostic 
category. These can include inborn genetic properties, viral infections, immune suppression 
and exogenous exposure to mutagens
188
. Additionally, it has recently been discovered that 
somatic mutations of tumor suppressors and oncogenes with high allelic frequencies and even 
with high clonal load are present in the hematopoietic systems of otherwise healthy mid-aged 
and elderly patients
189
. While implications of this phenomenon are not yet clear, it is possible 
that such mutations can predispose multiple and recurrent but clonally independent tumor 
formation in individuals who carry them. 
Clonally-unrelated relapses also have clinical implications: as they effectively are de novo 
neoplasms, high-dose second line therapies might not be the most suitable option for such 
patients. Instead, the use of a conventional first line therapies could be justified but this has to 
be evaluated by specifically designed prospective clinical trials
188
.  
 
Techniques for clonality testing 
Since B-cell lymphomas originate from different stages of developing B-cells, as clonal 
outgrowths of lymphocytes, they have a physiologically occurring clonality marker in the 
form of uniquely rearranged IG genes. Indeed, this feature has been exploited in research as 
well as in clinical setting, where confirmation of clonal lymphoid proliferation is sometimes 
an important component of a conclusive clinical diagnosis
72
. Thus, many different strategies 
were detected to assay genetic rearrangements between primary and subsequent occurrences. 
They include early analysis by Southern blotting, PCR-based techniques of locus 
amplification and fragment length comparison as well as recently introduced scanning of 
rearrangement spectrum by high-throughput sequence analysis
190
.  
The multiplex PCR approach that was introduced almost two decades ago remains the golden 
standard for clonality testing. By this technique standardized sets of consensus PCR primers 
are used to amplify different regions of the IGH and IGL loci. Then lengths of the generated 
amplicons are investigated by a preferred method (usually based on capillary electrophoresis). 
The assumption is that that clonally-related cases will have the same V(D)J rearrangements 
and thus identical fragment lengths, while in clonally-unrelated cases these lengths will be 
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different. In ambiguous cases, generated amplicons can be analyzed by sequencing the 
amplicons directly or after cloning and selection of individual plasmids. The multiplex PCR 
method is still preferred because of its high sensitivity, specificity, ability to analyze DNA 
from fresh- as well as formalin-fixed tissue DNA samples and relatively low price.  
Next generation sequencing (NGS) techniques have recently been successfully applied also 
for clonality testing
191–193
. Additional to advantages offered by the massive parallel 
sequencing approach and depending on the target enrichment techniques used, NGS can 
provide sequence information not only of a major clone, but also many secondary clones, 
including those, which represent healthy B-cell populations. This allows observing frequency 
dynamics of distinct subpopulations between multiple, particularly timely-separated samples. 
The NGS approach is also more sensitive, making it useful for minimal residual disease 
monitoring
194
. Although it is currently not yet widespread, it is likely that within next 5 years 
its use will dramatically increase. 
Clonal relationship between two different tumors can also be determined by studying other 
tumor-specific somatic events. For example, the presence of the same translocation with 
identical breakpoints can be used as an evidence for clonal relationship. However, tumors 
often acquire recurrent genetic alterations that affect same targets therefore the reliability of 
clonal relationship estimation depends on the number of different genetic loci interrogated. 
Genome-wide techniques such as array comparative genomic hybridization (aCGH) and 
whole exome or genome sequencing are suitable for this purpose
195–198
. Due to lack of other 
clonality markers the latter two techniques are most frequently used in demonstrating clonal 
relationships between two distinct solid tumors or a primary solid tumor and its (probable) 
metastasis. In lymphomas, aCGH and NGS was mostly used to determine clonal relationships 
between synchronous composite tumors and connection between primary indolent and 
aggressive transformed disease
199,200
.  
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2. AIMS 
2.1 To test the existence of clonally-unrelated recurrences and to 
investigate the genetic evolution of relapses in DLBCL 
Despite multiple demonstrations of clonally-unrelated relapses in lymphoid neoplasms, second 
DLBCL occurrence in the same patient is still generally regarded as a direct outgrowth of the 
primary tumor. As shown in other entities, clonal relationship or lack of it might have a 
prognostic value as well as a clinical importance. Therefore we aimed to test the existence of 
clonally-unrelated DLBCL relapses by investigating chromosomal copy number aberrations and 
nucleotide-level somatic alterations in paired primary and relapse DLBCL samples. 
The availability of paired samples also allowed tracking of tumor genetic progression. Recent 
findings in carcinomas as well as in other lymphoid neoplasms, such as follicular and mantle cell 
lymphoma, suggested branching mode of evolution in some cases. We wanted to extend these 
findings to DLBCL and test whether similar relapse patterns are characteristic to this 
heterogeneous lymphoid neoplasm.  
 
2.2 To identify recurrently occurring genetic alterations associated with 
relapsing as well as non-relapsing DLBCL 
Despite relatively successful first line R-CHOP treatment, 30-40% of DLBCL patients relapse or 
are refractory to initial therapy. Such patients have limited treatment options and generally 
unfavorable outcomes. Currently, the understanding of the molecular basis of DLBCL relapse is 
scarce. Only a few studies on paired primary-relapse/refractory DLBCL samples attempted to 
pinpoint the potential molecular drivers of the process. We therefore aimed to identify recurrent 
genetic lesions that happen at the transition between primary and relapse hoping to identify 
genetic culprits of recurrences. Furthermore, we included a cohort of primary non-relapsing 
DLBCL and contrasted their genetic profiles to these of relapsing DLBCL in order to identify 
potential markers, which would be useful in predicting at diagnosis whether tumor has or hasn’t 
the propensity to relapse.  
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2.3 To develop and to apply a technique for rare cell nuclei enrichment 
from archival formalin-fixed paraffin-embedded (FFPE) tissues by flow 
sorting and to enable comprehensive genetic analysis on the enriched 
sorted populations  
Prerequisite for the precise use of most of the genome-assaying techniques is that cells-of-
interest would constitute a significant part of the investigated sample. However, the biology of 
certain human malignancies, such as classical Hodgkin lymphoma, T-cell/histiocyte rich B-cell 
lymphoma and others does not fulfill this criterion. Additionally, such diseases are often rare. 
This means that samples are very limited and are often present only in a form of FFPE tissue 
blocks left-over after a diagnostic histological processing.  
Throughout the duration of my PhD studies I have been developing protocols that would allow 
efficient marker-based enrichment of FFPE tissue-derived nuclei by fluorescence-associated cell 
sorting (FACS) technique. In this work I present two papers where this technique was practically 
applied. The first study investigated copy number aberrations in LANA1-of-HHV8-enriched 
nuclei from two cases of primary effusion lymphoma. In the second study, MUM1-positive 
plasma cells were sorted to investigate genomic complexity of early post-transplant 
lymphoproliferative disorders.  
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3. RESULTS 
3.1 Distinct genetic evolution patterns of relapsing diffuse large B-cell 
lymphoma revealed by genome wide copy number aberration and 
targeted sequencing analysis. 
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Abstract 
Recurrences of diffuse large B-cell lymphomas (DLBCL) result in significant morbidity and 
mortality, but their underlying genetic and biological mechanisms are unclear. Clonal 
relationship so far is mostly addressed by the investigation of immunoglobulin (IG) 
rearrangements, therefore lacking deeper insights into genome-wide lymphoma evolution. We 
studied mutations and copy number aberrations in 20 paired relapsing and 11 non-relapsing 
DLBCL samples to test the clonal relationship between primaries and relapses, to track tumors’ 
genetic evolution and to investigate the genetic background of DLBCL relapses. Three clonally-
unrelated DLBCL recurrences were identified (15%), in which tumors showed no shared genetic 
characteristics. Also, two different patterns of genetic evolution were detected: (1) early-
divergent/branching evolution from a common progenitor in 6 patients (30%), and (2) late-
divergent/linear progression of relapses in 11 patients (65%). Analysis of recurrent genetic 
events identified early drivers of lymphomagenesis (KMT2D, MYD88, CD78B and PIM1). The 
most frequent relapse-specific events were additional mutations in KMT2D and MEF2B. 
Comparison of alterations between non-relapsing and relapsing DLBCL identified recurrent 
group-specific genetic events. Non-relapsing DLBCL had recurrent deletions of CYP7B1 and 
mutations of SOCS1 and RELN. Recurrent gains of 10p15.3-p13 in relapsing lymphomas 
containing PRKCQ and GATA3 were associated with a potential to relapse. 
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Introduction 
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm worldwide. 
While the majority of patients can be cured by existing therapeutic regimens, still about 30-40% 
relapse or are refractory to standard treatment. A DLBCL relapse is defined as appearance of 
new lesions after achieving complete remission for at least three months, and is linked to 
significantly increased morbidity and mortality
1
. Standard treatment of such patients consists of 
high-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT)
2
, and the 3-year 
overall survival is only about 50%
3
. 
Relapses of lymphoid neoplasms, even after long-lasting clinical remission, are generally 
regarded as direct outgrowths of the primary tumor
4–6
, although rare clonally-unrelated relapses 
have been documented
7–10
. Such unrelated recurrences point to an increased general risk for 
patients developing a second de novo neoplasm of the same diagnostic category, and raises the 
question of potential predisposition factors in these types of relapses. Clinically, the choice of the 
most effective treatment is complicated in such instances, i.e. HDT-ASCT or a standard primary 
regimen
4,7
.  
The gold standard for determination of a clonal relationship is analysis of immunoglobulin (IG) 
V(D)J gene rearrangement, which is unique for mature B-cells and is stably transferred to 
daughter cells during the process of clonal expansion
11
. Clonal relationship can also be 
determined at the genomic level by genome-wide approaches such as array-comparative genomic 
hybridization (aCGH) and deep sequencing
12–14
. 
Despite being a major cause of morbidity and mortality in DLBCL, genetic mechanisms of 
DLBCL relapse remain poorly characterized due to the paucity of sequential paired primary-
relapse samples. The potential of paired sample analyses to identify key genetic events in tumor 
evolution are evident from a study of DLBCL pairs by deep exome and IGH sequencing as well 
as studies addressing transformation of follicular lymphoma (FL) to DLBCL. These studies have 
shown recurrent alterations of REL, MYC, PIM1, CDKN2A and B2M, suggesting a functional 
importance
12,15–18
. 
In this study, we performed comprehensive characterization of 20 paired relapsing- and 11 non-
relapsing DLBCL samples and demonstrated clonally-unrelated relapses at the genomic level as 
well as two distinct genetic evolution patterns in clonally-related DLBCL relapses. Finally, we 
observed recurrent shared mutations suggesting early drivers of lymphomagenesis and recurrent 
group-specific genetic aberrations in non-relapsing and relapsing primary DLBCL, which might 
be linked to recurrences and treatment susceptibility, respectively.  
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Materials and Methods 
See supplementary information for the description of additional materials and methods. 
Samples 
Lymphoma samples were from the archive of the Institute of Pathology at the University 
Hospital Basel, Switzerland. In the relapsing cohort primary and relapse materials of patients 
diagnosed with DLBCL recurrences (n=20 pairs) after periods of complete remission were 
included. The non-relapsing cohort (n=11) consisted of well-preserved diagnostic biopsies of 
patients who had a single occurrence of DLBCL and were relapse-free for at least 7 years. 
Formalin-fixed, paraffin-embedded (FFPE) and fresh frozen (FF) (if available) tissues were used 
(see Table S1). A previously reported historic DLBCL cohort of over 250 cases brought into 
tissue microarrays was used to evaluate GATA3 overexpression
19
. Retrieval of tissue and data 
were performed according to regulations of the local institutional review boards and data safety 
laws. The study was approved by the Ethics Committee of North-Western and Central 
Switzerland (EKNZ 2014-252). 
aCGH data analysis 
aCGH data were assessed with a series of QC metrics and subsequently analyzed using Agilent 
Genomic Workbench v.7.0 software with the aberration detection algorithm ADM2
20
. Using 
derivative log2 spread ratio as the primary quality assessment criterion and manual inspection, 
microarrays were separated into multiple subgroups for which different ADM2 threshold values 
were applied. Subsequently, cumulative probe-based aberration frequency data was exported for 
each sample set (primaries of relapsing DLBCL, relapses, primaries of non-relapsing DLBCL) 
and further processed by a custom workflow programmed in R (http://www.r-project.org/).  
Variant calling and filtering 
Library construction and sequencing was successful in 19 of 20 (95%) relapsing DLBCL pairs 
and 11 (100%) non-relapsing DLBCL samples. Mutation identification was performed by the 
Variant caller plug-in IonTorrent software suite v4.4 using low stringency parameters, listed in 
Table S2. Variants were annotated with IonReporter software using Variant annotation workflow 
v4.4. Depth of coverage, coverage uniformity and number of variants called are summarized in 
Table S1. At the initial quality filtering, variants with Phred-based quality score <50, strand bias 
>0.75, and number of variant-supporting reads <10 were discarded from the analysis. Depending 
on the analysis application, different filtering workflows were used at the final variant filtering 
stage as depicted in Figure S1. Only exonic non-synonymous mutations were considered for the 
identification of recurrent mutations, while synonymous and non-exonic variants were 
additionally included for tumor evolution analysis. Pairs in which sequencing quality was low in 
one or both samples due to poor coverage uniformity (<70%) or exceptionally large mutation 
numbers (more than two standard deviations) were excluded from the evolutionary analysis and 
used only for identification of shared recurrent mutations.  
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Evolutionary analysis 
Lack of relationship was established when paired samples contained distinct IG chain 
rearrangements and/or no common chromosomal aberrations with identical breakpoints in all 22 
autosomes and the X chromosome. Clonal relationship was established when paired samples 
contained the same IG rearrangement and at least one chromosomal aberration with an identical 
breakpoint. The presence of shared mutations was not considered evidence of clonal relationship 
due to the lack of appropriate germline controls, but mutations were used for evolutionary 
distance estimation. Tumor evolution via a common progenitor was assumed in clonally-related 
cases when at least one homozygous or heterozygous deletion with a unique breakpoint was 
detected in the primary tumor, but was not present in the paired relapse sample. Evolutionary 
distance from a common progenitor was calculated using the adapted Jaccard’s formula for 
distance calculation between asymmetric binary attributes: d =  
𝑞
𝑝+𝑞
; here, q is the count of 
unique genetic alterations in primary or relapse tumor, and p is the count of shared genetic 
alterations
21
. The distance (d) can result in values between 0 and 1. In this application, d = 0 
implies that there are no private alterations (no progression from the common progenitor), while 
d = 1 implies the lack of shared genetic events between tumors, and thus maximal distance. 
Statistical analysis 
Descriptive statistics were used to characterize samples in both cohorts. Two-tailed Fisher’s 
exact test, Chi-square and Mann-Whitney U tests were utilized where appropriate to determine 
distribution differences between groups and to calculate the statistical significance of the 
differential recurrent aberrations between groups of samples. The Kaplan-Meier method was 
used to evaluate overall survival of DLBCL patients grouped by GATA3 expression. All 
statistical calculations were performed with MS Excel 2013, SPSS 22 or R statistical package. 
Statistical significance threshold of p<0.05 was assumed in all analyses.  
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Results 
Relapsing DLBCL show more advanced tumor stages and stronger BCL2 expression  
Available clinical and pathological characteristics of the patient cohorts are summarized in Table 
1, Figure 1 and Figure S2. Therapy information was retrieved for 27 of 31 patients. First line 
therapy with curative intent was administered in all but one patient and consisted of CHOP (n=1) 
or R-CHOP (n=25) with (n=4) or without irradiation (n=23). Depending on the risk factors, 
intrathecal chemotherapy was administered in 9 patients (4 who relapsed and 5 who did not). 
Median age at initial diagnosis was 66.5 years for the relapsing DLBCL cohort and 74 years for 
the non-relapsing cohort (p>0.05); the former cohort presented with more advanced disease 
stages (p=0.029).  
Of the classifiable samples (n=18) in the relapsing DLBCL cohort, 12 primary tumors were of 
non-germinal center B cell-like (non-GCB) and 6 of GCB origin (Figure 1 and Table S3). In the 
non-relapsing DLBCL cohort, 10 of 11 cases could be classified, 5 of GCB origin and 5 non-
GCB (see supplementary results for information on cell of origin changes at relapse and Figure 
S2). 
Primaries of relapsing DLBCL expressed higher levels of BCL2 than non-relapsing (median 
positivity 80%±29 vs 35%±29, p=0.027). When positivity was evaluated by applying the cut-off 
value of 70%
22
, this difference remained significant (positive 14/19 vs 2/10, p=0.008). No 
significant differences in expression of C-MYC, BCL6 or MIB1 were observed between the 
cohorts (Table S3).  
Clonally-unrelated DLBCL relapses 
Analysis of genetic data within the individual pairs of primary and relapsed DLBCL identified 
clonally-unrelated recurrences and two different evolution patterns among clonally-related 
DLBCL relapses (Figure 1). Interestingly, intra-tumoral heterogeneity was evident in multiple 
instances both at the primary and relapse stages (Figure S3).  
Clonally-unrelated relapses were detected in 3 patients (cases 1, 15 and 17). Primary and relapse 
tumors in these pairs showed no shared chromosomal aberrations. Even when certain 
chromosomal loci were aberrant in both samples, breakpoint regions never matched (Figure 2A). 
Targeted sequencing revealed no shared single nucleotide mutations in cases 1 and 17, but 2 
shared single nucleotide variants in EP300 and CD79A in sample 15. As expected, from the 
evolutionary point of view, clonally-unrelated tumors showed maximal dissimilarity as there 
were no or very few genetic events in common between primary lymphoma and relapse (Figure 
3A). Lack of clonal relationship in cases 1 and 15 was additionally confirmed by fragment size 
and sequence analysis of the rearranged IG genes (Figure 2B and Figure S4). However, attempts 
to amplify IG rearrangement regions in sample 17 were unsuccessful, likely due to heterozygous 
deletions of the IGH locus in both primary and relapse tumors and the deletion of the IGK locus 
in the primary tumor. Compared to other relapses (see later), clonally-unrelated relapses tend to 
occur latest after initial lymphoma presentation. Times to relapse were 103, 32 and 81 months 
(median 81 months) in cases 1, 15 and 17, respectively. 
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Two patterns of clonally-related DLBCL relapse 
The first genetic pattern within the group of clonally-related relapses, early-divergent/branching 
evolution from a common progenitor, was detected in 6 cases. In addition to shared aberrations 
with identical breakpoints between primary and relapse, primary tumors had CNA, most 
importantly homozygous and heterozygous deletions, which were not present in the subsequent 
relapse samples (Figure 2C). Taking into account mutations detected by targeted NGS, most 
(5/6) of the primary tumors characterized by this pattern showed larger genetic distances from 
the putative common progenitor than that seen in the relapses (Figure 3B and Figure S5A), 
suggesting that the divergence of primary and relapse tumor clones occurred early. This is also 
supported by the longer median time to relapse, in this cohort 54 months (range 18-141 months), 
compared to relapses with late-divergent evolution (see later). Clonal relationships in all 6 cases 
were confirmed by detection of identical IGH rearrangements and presence of shared single 
nucleotide mutations (median 5, range 1-23).  
The second and the most frequent relapse pattern (detected in 11 cases), late-divergent/linear 
evolution with or without progression, most closely reflects the current concept of DLBCL 
recurrence. In cases characterized by this pattern, primary tumors had no private CNA compared 
to relapses (Figure 2D), yet a limited degree of divergence was evidenced by small numbers of 
private single nucleotide mutations in primary tumors. Nevertheless, these private mutations 
yielded only a minimal genetic distance from the putative common progenitor population, which 
was, in all cases, smaller than the genetic distance from the common progenitor to relapse 
(Figure 3C and Figure S5B). At relapse, the majority of cases (9/11) showed increased numbers 
of genetic alterations despite the fact that the median time to relapse was shortest in this group 
(17 months, range 8-53 months). 
Recurrent genetic alterations in relapsing and non-relapsing DLBCL  
The most frequent CNA in primaries of both relapsing and non-relapsing DLBCL were 
heterozygous deletions of chromosome 6q (affecting PRDM1) in 16 of 31 (52%) cases as well as 
gains of large parts of chromosome 7 and 18, 10/31 (32%) and 12/31 (39%) cases, respectively. 
The most frequently mutated gene overall was KMT2D, which harbored mutations in 10/16 
(63%) of clonally-related relapsing DLBCL and 5/11 (46%) of non-relapsing DLBCL cases. 
Mutations were scattered across many exons of this gene without hotspot. Other frequently-
mutated genes included CD79B, BTG1 and PIM1 (Figure 4 and Table S4).  
Losses of 6q22.31-q22.33 and gains of chromosome 7 were the most frequent CNA occurring 
early in the progenitor cell population before divergence. Mutations of KMT2D (7/16), CD79B 
(5/16), MYD88 (4/16) and PIM1 (4/16) were shared in clonally-related tumor pairs, suggesting 
that they occurred early and were drivers of lymphomagenesis. Of note, mutations in the latter 
three genes were restricted to DLBCL of non-GCB cell of origin and were concurrent in 3 
tumors.  
Most of the tumors acquired multiple chromosomal gains and losses at relapse, but no recurrent 
CNA could be identified. Mutations in KMT2D were the most frequent relapse-specific sequence 
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alteration, occurring in 7 of 16 (44%) evaluated relapses. The second most frequently mutated 
gene at relapse was MEF2B, affecting 3 of 16 cases (19%).  
Comparison of CNA between primaries of relapsing DLBCL and non-relapsing DLBCL 
identified several differentially aberrant regions (Figure 5 and Table 2). Predominantly, DNA 
copy gains emerged that were more frequently observed in non-relapsing DLBCL, the most 
significant of which were amplifications in the short arm of chromosome 2, spanning and 
continuing downstream of the lymphoma oncogene C-REL. Other gains affected parts of 
chromosomes 6, 9, 13, 14, 19 and 22, and were also more prevalent in the non-relapsing DLBCL 
cohort. These alterations affected a total of 553 protein-coding genes, 14 of which were included 
in the COSMIC cancer gene census list. 
 The only recurrent CNA characteristic to primaries of relapsing DLBCL was a gain in 10p15.3-
p13, which contained more than 70 protein-coding genes including GATA binding protein 3 
(GATA3) and protein kinase C-theta (PRKCQ). To test the prognostic significance of GATA3 
overexpression in DLBCL 23 of the study cases with sufficient material and a well-characterized 
historic DLBCL microarray of 250 evaluable cases was immunohistochemically examined (see 
Supplementary results and Figure S6 and S7). A reliable anti-PRKCQ antibody for 
immunohistochemistry is currently not available. 
 The only recurrent differential copy number loss between relapsing and non-relapsing DLBCL 
primaries was a heterozygous deletion of 8q12.3, affecting cytochrome 7 beta polypeptide 1 gene 
(CYP7B1), which was found exclusively in the non-relapsing group. At the nucleotide level, two 
genes, RELN and SOCS1, were found to be mutated in 3 of 11 non-relapsing DLBCL cases, but 
were not affected in any of the relapsing DLBCL (p= 0.052).  
Discussion 
First presentations and subsequent recurrences of lymphomas are generally regarded as direct 
outgrowths of the primary tumor clone
4,6
. However, cases of clonally-unrelated relapses have 
been documented in indolent and aggressive lymphoma transformations
5,23
, as well as in 
Hodgkin and composite lymphomas
9,24,25
. Reports on unrelated relapses of DLBCL are scarce. 
One study found two equivocally unrelated recurrences within a group of 13 late-relapsing 
DLBCL
4
, and another reported five late central nervous system relapses of DLBCL unrelated to 
the respective primaries
26
. These studies relied on multiplex PCR-based determination of clonal 
relationship, a technique that, while robust in addressing clonal relationship, is based on the 
analysis of a single or a few genetic loci, providing no insight into the underlying genetic 
composition of the respective diseases. Array-CGH microarrays have been previously used to 
establish relationship between multiple lesions or primaries and metastases in solid tumors
13,27,28
. 
Here, we demonstrate that this approach can also be successfully applied to analysis of paired 
lymphoma samples. PCR-based clonality analysis combined with genome-wide copy number 
arrays and targeted massive parallel sequencing unequivocally proved the existence of clonally-
unrelated DLBCL recurrences and exposed the profound genetic composition differences 
between primary and relapse tumors. Moreover, our approach advantageously clarified clonal 
relationship in instances where V(D)J rearrangements could not be amplified or interpreted, as in 
our case 17.  
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In agreement with other reports, clonally unrelated relapses in our study occurred after relatively 
long intervals from the initial DLBCL diagnosis, thus being considered late (32 months) or very 
late (81, 103 months). The reasons for a second “de novo” appearance of DLBCL in the same 
patient are unclear, but could be related to continuous exogenous hazards, genetic predisposition, 
treatment-induced DNA damage, acquired mutations in the (hemato-)lymphopoietic stem cell 
pool or prolonged immunosuppression. The presence of clonal somatic mutations at low 
frequency in non-malignant hematopoietic cells is a recently described phenomenon
29
. One of 
the clonally-unrelated cases in our cohort (case 15) showed the presence of two mutations, an 
inactivating nonsense mutation in EP300 and a missense mutation in CD79A, in both primary 
and relapse tumors, which were otherwise genetically distinct with different IGH rearrangement 
and EBV status (EBV+ primary, EBV- relapse). Thus, it is possible that these two mutations 
were inherent to a putative B-lymphopoietic progenitor cell pool and increased the chance of this 
patient developing a second lymphoid malignancy. Additionally, the patient’s clinical history of 
immunosuppression due to solid organ transplantation suggests a second risk factor, i.e. 
immunosuppression. Lack of clonal relationship (i.e. second de novo DLBCL and not a progress 
of the initial DLBCL) may have played a role in the remarkably successful treatment of the 
relapse tumor with lenalidomide monotherapy, after which the patient achieved lasting clinical 
remission
30
. Also notable in this context is the clinical history of patient 17, diagnosed with 
primary testicular DLBCL followed 81 months later by an unrelated DLBCL of the central 
nervous system. Interestingly, both lymphomas occurred at immuno-privileged sites, supporting 
possible underlying immune deregulatory mechanisms or immunogenetic defects as unifying 
risk factors. Importantly, clonally-unrelated DLBCL recurrences in the same patient and 
demonstration of their different genetic constitutions raise a question of immediate clinical 
impact, i.e. whether adjusted treatment regimens could be applied. Theoretically, standard first-
line treatments might be efficient for such patients, thus abrogating the adverse side effects of 
high-dose myeloablative chemotherapy with the need of ASCT. However, given the rarity of 
unrelated relapses and the significant therapeutic consequences therefrom, this subject requires 
assessment on a selected, large-scale cohort of clinical samples. 
The existence of two different patterns of clonally-related DLBCL relapses in our study 
resonates well with other findings from genomic studies on paired transformed FL and relapsing 
DLBCL cohorts. Pasqualucci et al. reported divergent evolution from a common progenitor as 
the more frequent mode, occurring in 10 cases, while linear progression was detected in only 2 
instances
17
. Okosun et al. found that all transformed FL evolved from either rich (n=8) or sparse 
(n=2) ancestral common progenitor clones
18
. Likewise, by sequencing rearranged V(D)J 
junctions of paired primary and relapse DLBCL samples, Jiang et al. identified early- and late-
divergent patterns of clonal evolution
12
. All three studies observed shared mutations between 
clonal populations of primaries and recurrences, indicating a common clonal origin, whereas 
other mutations were unique for each manifestation. This is analogous to our identification of 
shared chromosomal aberrations with identical breakpoints and unique CNA in primary tumors 
that were not detectable in the subsequent relapse samples in the 6 divergent/branching evolution 
pairs. The 11 pairs that appeared to follow a more linear evolution path by CNA analysis, but 
had low number of single nucleotide mutations, are reminiscent of the “rich common progenitor” 
or “late-divergent categories” described in the latter two studies. These relapse patterns are 
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characterized by evolutionary late separation of subclones from a common progenitor and, 
therefore, bear minor genetic distances between the respective manifestations. 
We hypothesized that genetic factors are present in the primary DLBCL tumors that determine 
whether the tumor will or will not recur. To test this hypothesis, we compared CNA and 
mutational data between primary relapsing and primary non-relapsing DLBCL cohorts and 
identified genetic events that occurred more frequently in one or the other group. Surprisingly, 
the majority of recurrent genomic aberrations were detected in the non-relapsing cohort. 
Differentially amplified regions in this group contained oncogenes (FLT3, PDGFB, MKL1) as 
well as tumor suppressors (RB1, BRCA2, STK11, EP300). The precise significance of these 
genes in the context of successful treatment response needs additional investigation. The only 
recurrent differentially-deleted region was 8q12.3 in non-relapsing lymphomas; it contained a 
single gene, CYP7B1, which encodes a multi-functional protein of cytochrome P450 family that 
primarily acts as steroid hydroxylase and is directly implicated in bile acid synthesis
31
 and 
steroid metabolism
32
. Its genetic defects are linked to severe liver insufficiency in newborns and 
adult neuropathies
33
. Interestingly, prednisone, a steroid drug and a component of the CHOP 
regimen, has been suggested as a metabolic substrate of CYP7B1
34,35
. Moreover, vincristine and 
doxorubicin, two other components of CHOP, are known to be catabolized and thus inactivated 
by the P450 complex. Taken together, loss of CYP7B1 might increase sensitivity to CHOP and 
partially explain why this recurrent chromosomal deletion is present in the non-relapsing 
DLBCL group. 
In our study, SOCS1 mutations were exclusive to the non-relapsing cases. It has been shown that 
truncating mutations in tumor-suppressor SOCS1 are prognostic for a favorable DLBCL 
outcome
36
. Indeed, 2 of 3 affected cases had nonsense mutations truncating the SOCS1 protein, 
and the third case had missense mutation in the kinase inhibitory domain (KIR), which is 
required for binding Janus kinases and suppressing their activity. We did not find any known 
associations between RELN mutations and decreased propensity to relapse.  
Paired DLBCL exome sequencing study reported that mutations within histone modifiers are 
potential driver mutations in DLBCL
12
, a finding we partially confirm by identification of 
KMT2D as the most commonly mutated gene in both primary and relapse tumors in our cohort. 
Additionally, our data indicate that the MYD88 L265P mutation, the CD79B Y197C mutation 
and PIM1 mutations are early events in DLBCL genetic evolution that are shared in clonally-
related tumor pairs, suggesting they played a driver role in lymphomagenesis.  
Numerous studies already addressed the negative prognostic value of BCL2 expression in 
DLBCL
22
 [and references therein]. The significant differences in BCL2 expression between 
primaries of relapsing and non-relapsing DLBCL observed in our cohort corroborate these 
observations, reappraising the negative prognostic importance of BCL2 in DLBCL.    
In conclusion, genome-wide CNA profiling and targeted sequence analysis of paired primary and 
relapse DLBCL samples reliably demonstrates, for the first time, the existence of clonally-
unrelated DLBCL recurrences at the genomic level. Further, our results show that genetic 
evolution of DLBCL at relapse occurs through early or late divergence from a common 
progenitor clone. Finally, we demonstrate differentially aberrant regions between primary 
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relapsing and non-relapsing DLBCL containing genes that are potentially involved in sensitivity 
to treatment as well as propensity to relapse potential.  
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Figures 
 
  
Figure 1. Disease history overview of the relapsing DLBCL cohort. Cell of origin is represented by 
symbol shape and clonal relationship by color. Numbers centering the symbols represent respective C-MYC 
and BCL2 co-expression double-hit scores. Stacked symbols (cases 1 and 5) represent two parts of the same 
tumor profiled by aCGH where intratumoral heterogeneity was detected (see Figure S3). At the right side, 
sizes of the amplified IGH rearrangement products are indicated for clonally unrelated cases. Abbreviations: 
na – not accessed; np – not processed. 
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Figure 2. Different modes of DLBCL relapse. A. A genome-overview plot of a clonally unrelated pair 
(case 1) is shown. Genome position is represented on the abscissa and the log2 ratio on the ordinate. 
Moving average of the primary (red) and the relapse (blue) is plotted. Regions above and below the log2 
ratio value of 0 represent gain or loss of DNA, respectively. None of the aberrations match between primary 
and relapse tumors. For example, chromosome 3 is highly aberrant (magnified, color tint represent the start 
and end of the aberrant region) in both cases, but breakpoints of gains and losses do not match. B. 
Amplified FR3 and FR2 region of IGH V(D)J rearrangements show distinct sizes between both DLBCL 
occurrences and FR2 sequences align to different families of IG variable genes. C. An example of a 
clonally-related DLBCL pair (case 8), in which primary and relapse tumors emerged through early-
divergent/branching evolution from a common progenitor cell clone. Both tumors share some chromosomal 
aberrations (chromosomes 6, 13, 21) confirming their shared origin, but aberrations unique to the primary 
tumor (green arrows) suggest separation and independent evolution of the tumor-initiating clones. D. An 
example of a clonally-related DLBCL pair (case 4) in which the relapse emerged through late-
divergent/linear evolution from the common progenitor population tumor but gained some additional 
chromosomal aberrations. * -not called by the CNA detection algorithm. 
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Figure 3. Genetic evolution patterns in relapsing DLBCL. A. Schematic representation of clonally-
unrelated DNA relapses showing few or lack of unifying genetic alterations and a maximal genetic distance 
from one another. B. Primary tumors belonging to the early-divergent/branching pattern of DLBCL 
recurrence have high numbers of private genetic alterations and, therefore, large genetic distance from the 
putative common progenitor. In these cases relapses are genetically less distant to the common progenitor 
than primaries. C. In the late-divergent evolutionary pattern, primary tumors are genetically very close to 
the putative common progenitor, while relapses show higher divergence. 
Numbers inside circles represent a combined count of mutations and copy number aberrations in the 
respective population. Circle sizes are scaled according to the number of genetic alterations. Dashed purple 
area symbolizes the time from putative divergence of populations to occurrence of primary lymphoma, 
which is unknown. Red – genetic alterations unique to primary tumor. Blue – genetic alterations unique to 
relapse. Grey circle – putative common progenitor. The genetic distance from the common progenitor is 
plotted on the y axis; at the top of the x axis for the primary tumor, at the bottom for the relapse. 
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Figure 4. Non-synonymous variants in studied DLBCL cases 
A heatmap plot of all non-synonymous variants that were detected by targeted NGS. Genes are ordered left-
to-right according to the decreasing number of mutations observed. * – samples in relapsing DLBCL 
cohort, which were evaluated only for shared mutations due to sub-optimal sequencing quality.  
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Figure 5. Differential comparison of chromosomal copy number aberrations between primary 
relapsing (n=20) and non-relapsing (n=11) DLBCL. The upper part of each graph plots the frequency of 
aberrations (%, amplification in positive, deletion in negative scale) against the chromosomal position (base 
pairs). In the bottom panel, p-values are plotted. Dark colors represent aberrations more frequently detected 
in the non-relapsing set of DLBCL, while light colors represent aberrations characteristic of the relapsing 
set of DLBCL. Genes affected in regions with p-value <0.1 are listed in Table S5. 
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Table 1. Clinical characteristics of the study cohorts 
Nr Gender Age, y Stage Primary location Follow-up, m Therapy Time to relapse, m 
Relapse 
location 
Dead 
Relapsing cohort 
1 F 71 NA Bronchus 104 NA 103 Soft tissue 1 
2 M 62 NA Lymph node 27 6x R-CHOP 11 Lymph node 1 
3 M 72 IIIA Lymph node 12 6x R-CHOP 9 Stomach 1 
4 M 80 IVA Lymph node 19 6x R-CHOP 8 Lymph node 1 
5 M 61 IVA Lymph node 27 6x R-CHOP+2x R-mono, ITH, irradiation 26 Duodenum 1 
6 F 81 IIA Lymph node 6 6x R-CHOP, irradiation 10 Lymph node NA 
7 F 74 IIB Upper abdomen 41 Palliative 5x R+gemcitabine 17 Muscle 1 
8 M 37 IIA Soft tissue upper arm 32 6x CHOP, irradiation 19 Bone  NA 
9 M 49 IIIA Lymph node 51 6x R-CHOP 33 Brain 1 
10 F 77 IVB Lymph node 25 6x R-CHOP, ITH 25 Lymph node NA 
11 M 75 IVB Lymph node 124 8x CHOP, ITH 53 Chest wall 1 
12 F 29 IIIB Lymph node 116 8x R-CHOP 18 Lymph node 0 
13 F 56 IV Lymph node 74 6x R-CHOP, ITH 19 Lymph node NA 
14 M 71 IIA Lymph node 84 6x R-CHOP 74 Lymph node 0 
15 F 42 NA Lymph node 39 6x R-CHOP+2x R-mono 32 
Small 
intestine 
0 
16 M 50 NA Lymph node 126 NA 123 Soft tissue 0 
17 M 42 IIA Testicle 147 8x R-CHOP, ITH 81 Brain 0 
18 M 71 NA Eye ball 141 NA 141 Lymph node 0 
19 F 90 NA Lymph node 11 NA 11 Omentum  0 
20 F 31 IIA Lymph node 19 6x R-CHOP 18 Lymph node 0 
Non-relapsing cohort 
21 F 64 IVB Colon 119 8x R-CHOP, ITH NA NA 0 
22 F 83 IVB Lymph node 67 6x R-CHOP NA NA 0 
23 M 74 IIIA Lymph node 116 6x R-CHOP NA NA 0 
24 M 84 IIIA Intranasal 51 6x 80% R-CHOP, ITH NA NA 0 
25 M 83 IA Tounge 78 6x R-CHOP NA NA 0 
26 M 65 IV Lymph node 115 8x R-CHOP, ITH NA NA 0 
27 M 36 IIA Maxillary sinus 118 6x R-CHOP, ITH NA NA 0 
28 F 57 IA Vaginal mucosa 99 6x R-CHOP NA NA 0 
29 M 53 IA Lymph node 107 6x R-CHOP NA NA 0 
30 M 84 IA Lymph node 71 3x R-CHOP, irradiation NA NA 0 
31 M 84 IA Lymph node 78 6x 80% R-CHOP NA NA 0 
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Abbreviations: 1-dead; 0-alive; CHOP-cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone; F-female; ITH-intrathecal chemotherapy; M-
male; m-months; NA-not available; R-Rituximab; y-years.  
Table 2. Differentially aberrant chromosomal regions between relapsing and non-relapsing DLBCL 
Chromosome Start Stop Cytoband p-value Cancer census gene* 
CNA in 
relapsing 
DLBCL 
CNA in non-
relapsing 
DLBCL 
Non-relapsing DLBCL   
Amplifications 0/20 5/11 
chr2 64050753 65340372 p14-15 0.0027  0/20 4/11 
chr2 64119395 66009092 p14 0.0105  0/20 4/11 
chr13 57093042 71055517 q21.1-21.33 0.0105  0/20 4/11 
chr14 19376761 20397731 p11.2 0.0105  0/20 4/11 
chr2 62790398 64031168 p15 0.0132  1/20 5/11 
chr6 5793643 11076650 p25.1-24.2 0.0132  1/20 5/11 
chr2 65994717 75189618 p14-12 0.0367 DCTN1 0/20 3/11 
chr13 19752698 57073684 q11.2-21.1 0.0367 
BRCA2, LHFP, CDX2, 
LCP1, RB1, FLT3 
0/20 3/11 
chr22 35653033 43386781 q12.3-13.2 0.0367 
MKL1, PDGFB, MYH9, 
EP300 
0/20 3/11 
chr19 578539 1272710 p13.3 0.0377 STK11 3/20 6/11 
chr2 59987586 63605603 p15 0.0416  1/20 4/11 
chr9 30321407 39058117 p21.1-13.1 0.0416 FANCG 1/20 4/11 
chr13 71081217 71324117 q21.33 0.0416  1/20 4/11 
chr19 275924 335170 p13.3 0.0416  1/20 4/11 
Deletions   
chr8 65579491 66023718 q12.3 0.03671  0/20 3/11 
Relapsing DLBCL   
Amplifications   
chr10 269756 838046 p15.3-13 0.0116 GATA3 9/20 0/11 
*http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ accessed in September, 2015 
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Supplementary information 
Supplementary methods  
Immunohistochemistry 
Immunohistochemistry (IHC) was performed on serial tissue sections using an automated immunostainer 
Benchmark XT (Ventana/Roche, Tucson, AZ, USA) with a biotin-streptavidin-peroxidase detection 
system according to manufacturer’s protocols. All primary antibody clones, incubation- and antigen 
retrieval conditions as well as cut-off values used to determine tissue positivity are summarized in Table 
S6. Cell of origin (COO) classification was done according to the so-called Tally algorithm
1
.  
Assessment of IGH rearrangements 
A PCR-based assay for IG V(D)J rearrangements was performed with consensus FR2 and FR3 as well as 
J primers, as previously published
2
. Examination of the PCR products was carried out with the high 
resolution fragment length analyzer ABI 310 (Applied Biosystems, Foster City, CA, USA). 
Rearrangements were evaluated primarily by interpretation of the fragment lengths of products amplified 
with the FR3 primers. If this result was inconclusive, Biomed-2 primers targeting the FR2 region and/or 
kappa light chain-gene rearrangements were used (Invivoscribe Technologies, San Diego, CA, USA). 
Clonal rearrangements were defined as prominent, single-sized amplification products within the 
expected size range. Fragments suggesting clonally-unrelated recurrences were cloned into pGEM-T 
(Promega, Madinson, WI, USA) plasmids and Sanger-sequenced to unequivocally confirm different 
clonal origin. Sequences were analyzed with the IgBLAST tool
3
. 
DNA extraction  
H&E- and CD20-stained sections of FFPE blocks or FF tissues were reviewed by A.T. to evaluate tumor 
content. Only tissues with >70% tumor content were used. Depending on the distribution of tumor cells, 
25µm-thick sections were cut or punches were taken from the tumor-rich tissue areas. Prior to overnight 
Proteinase K digestion, paraffin sections were deparaffinized and rehydrated by serial xylene and ethanol 
washes, respectively. Genomic DNA (gDNA) was extracted by automation using Maxwell® 16 FFPE 
plus LEV DNA Purification Kit (Promega, Madison, WI, USA). gDNA from samples with extremely 
scarce tumor material was isolated by the phenol-chloroform extraction as described previously
4
. Yields 
were quantified by the Qubit assay (Life Technologies, Eugene, OR, USA).  
Array-CGH 
At least 100ng of gDNA from each sample and 500ng of commercial 46 XX reference gDNA (Promega, 
Southampton, UK) were used. Reference gDNA was heat-fragmented at 95ºC for 35 minutes. FFPE 
tissue-derived gDNA needed no additional digestion. Sample DNA extracted from FF tissues was heat-
fragmented to 400-600 bp in average. DNA fragmentation was evaluated by gel electrophoresis and 
subsequent image analysis with the ImageJ software (http://imagej.nih.gov/ij/index.html, version 1.48). 
Samples and references were labeled with Cy-5 dUTP and Cy-3 dUTP, respectively, using the BioPrime 
aCGH genomic labeling system (Invitrogen, Carlsbad, CA, USA). Success of labelling was evaluated by 
the Nanodrop assay (Thermo Fischer Scientific, Waltham, MA, USA) before mixing and hybridization to 
180k CGH arrays (Agilent Technologies, Santa Clara, CA, USA) for 24 hours in a rotating oven at 65ºC. 
All microarray slides were scanned with an Agilent 2565C DNA scanner and the images were processed 
with Agilent Feature Extraction 10.7 using default settings. 
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Targeted NGS 
Target enrichment panel was designed to include genes and their hotspots that are most frequently 
mutated B-cell lymphoid neoplasms according to the COSMIC database (release v70) and manual 
overview of the literature. 68 genes were included (Table S7). The designed panel comprised of 933 
amplicons in 4 primer pools (234 amplicons/pool in average). Mean primer length was 110bp (range 64-
137bp) making it suitable to amplify targets in the fragmented archival FFPE tissue-derived gDNA. 
Target amplification, library construction and sequencing were carried out according to recommendations 
of the manufacturer (Thermo Fisher Scientific, Carlsbad, CA, USA). Shortly, 10ng of FF or 15ng of 
FFPE DNA quantified by Qubit was used for target amplification in each primer pool. 17 and 20 PCR 
cycles were used for FF and FFPE DNA, respectively. Then amplicons from pools 1-3 and pools 2-4 
were combined, primer sequences were digested and barcoded adaptors were ligated. Bead enrichment 
and chip loading was performed with an automated IonChef instrument. Libraries of 4 samples were 
combined and sequenced in one IonTorrent 318v2 chip with IonPGM sequencer. 
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Supplementary results 
Retention and change of cell of origin (COO) in DLBCL relapses 
Within 15 pairs, to which the Tally algorithm
1
 could be reliably applied in both primary and relapse, COO 
change was documented in 2 cases (case 5 and case 15). In both cases, transition occurred from GCB-like 
to non-GCB-like phenotype.  
Case 15 was a clonally unrelated DLBCL relapse in which this “switch” is likely explainable by the 
independent cellular origin of the respective tumor occurrences.  
None of the cases with early-divergent/branching pattern of relapses showed a COO change at relapse; 
all but one primary tumor belonging to this category had a non-GCB COO.  
In the group with late-divergent/linear pattern of relapses 3/11 cases were of GCB COO, one of them 
(case 5) relapsed as a non-GCB DLBCL 27 months later. The changed COO in this case might be on the 
one hand related to micro-environmentally induced or progression-related gene expression pattern 
changes respecting LMO2 (80% positive tumor cells in the primary vs 20% in the relapse) and FOXP1 
(90% positive tumor cells in the relapse vs 25% in the primary) since the primary was diagnosed on an 
affected lymph node, while the relapse affected the duodenum 26 months later. On the other hand, and 
more probably, it might simply reflect the genuine insufficiency of immunohistochemical algorithms for 
error-free COO determination
5
. 
Expression frequency and prognostic significance of GATA3 in DLBCL 
Altogether 23 of the study cases could be analyzed. Of the 16 relapsing DLBCL, 3 (19%) expressed 
GATA3 compared to 1 of the 7 non-relapsing DLBCL (14%). The expression pattern was nuclear, 
weaker compared to tumor-infiltrating small T-cells, and present in 10 to 90% of tumor cells. There was 
no clear correlation between GATA3 expression and amplifications 10p14-15.  
 
 
Figure S6. GATA3-positive DLBCL. A. DLBCL expressing GATA3 in 90% of the tumor cells. B. 
DLBCL showing weak expression (weaker than the small tumor-infiltrating T-cells) of GATA3 in 15% 
of the large tumor cell nuclei. 
A B 
RESULTS 
 
59 
 
 
Figure S7. Survival of GATA3-positive and GATA3-negative DLBCL patients. Among 250 eligible arrayed cases
6
, 
only 12 DLBCL (5%) expressed GATA3. There were 128 adverse events in the 238 GATA3-negative patients 
(54%) compared to 9 of 12 (75%) in the GATA3-positive subgroup. Although the survival curves drifted apart, no 
significant outcome difference was suggested (p=0.091). 
The observed rare expression of GATA3 and lack of correlation to 10p14-15 amplifications as well as 
lack of significant prognostic impact in DLBCL, despite significantly more frequent 10p14-15 
amplifications in primaries of relapsing DLBCL, is likely explainable by one limitation of aCGH, i.e. that 
gains of genetic material do not directly or indisputably imply increased expression of genes located in 
the affected regions.  
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Supplementary tables 
Table S1. NGS quality parameters and case allocation for the analysis application 
  PRIMARY  RELAPSE     
Case Nr. 
Mean 
coverage 
Coverage 
uniformity 
Variants 
called* 
Mean 
coverage 
Coverage 
uniformity 
Variants 
called* 
For 
evolution 
analysis 
For recurrent 
mutation 
analysis 
analysis 
1 2819 47 1775 2331 82 60 NO YES 
2 - - - - - - - - 
3 2712 95 49 1215 82 2139 NO YES 
4 1283 94 87 1581 87 68 YES YES 
5 834 95 87 1636 46 117 NO YES 
6 566 77 1616 1182 94 158 NO YES 
7 1330 91 2137 1366 94 446 NO YES 
8 1042 91 71 825 90 302 YES YES 
9 603 95 80 830 93 286 YES YES 
10 979 96 50 879 90 105 YES YES 
11 997 92 1287 850 88 932 NO YES 
12 818 90 2014 1297 94 72 NO YES 
13 689 96 105 1065 96 51 YES YES 
14 1121 95 114 1419 94 67 YES YES 
15 821 95 161 1233 94 84 YES YES 
16 844 95 107 848 95 85 YES YES 
17 945 94 223 1164 94 86 YES YES 
18 635 95 133 1011 96 83 YES YES 
19 910 96 96 673 94 181 YES YES 
20 709 95 131 1125 96 59 YES YES 
21 549 95 74 - - - NO YES 
22 794 93 153 - - - NO YES 
23 1100 95 94 - - - NO YES 
24 1681 90 76 - - - NO YES 
25 1255 99 122 - - - NO YES 
26 887 95 140 - - - NO YES 
27 954 95 70 - - - NO YES 
28 1149 94 97 - - - NO YES 
29 1300 95 96 - - - NO YES 
30 1300 94 102 - - - NO YES 
31 1141 94 101 - - - NO YES 
*
number of variants called by the variant caller, before manual filtering 
Red – samples with poor sub-optimal sequencing quality 
Blue – fresh-frozen samples  
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Table S2. Torrent variant caller parameters used for the intial identification of variants. 
Parameter Value 
snp_min_allele_freq 0.02 
snp_strand_bias 0.95 
hotspot_min_coverage 6 
snp_strand_bias_pval 0.01 
position_bias 0.75 
hotspot_min_allele_freq 0.01 
snp_min_variant_score 6 
mnp_min_variant_score 15 
hotspot_strand_bias 0.95 
hp_max_length 8 
filter_insertion_predictions 0.2 
indel_min_variant_score 6 
indel_min_coverage 15 
heavy_tailed 3 
outlier_probability 0.005 
position_bias_ref_fraction 0.05 
indel_strand_bias_pval 1 
data_quality_stringency 6.5 
snp_min_cov_each_strand 0 
indel_as_hpindel 0 
mnp_strand_bias 0.95 
mnp_strand_bias_pval 1 
hotspot_strand_bias_pval 1 
hotspot_min_variant_score 6 
hotspot_min_cov_each_strand 2 
do_mnp_realignment 1 
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Table S3. Detailed immunophenotypic characteristics of the studied cases 
Relapsing 
 
CD10 GCET LMO2 BCL6 MUM1 FOXP1 MIB1 BCL2 C-MYC GATA3 COO 
1 
P NA +(dim) + NA - - NA NA +(40%) NA GCB 
R +(100%) +(90%) +(100%) +(80%) -(25%) +(90%) NA -(0%) +(40%) NA GCB 
2 
P - - - NA -(40%) +(90%) NA +(70%) -(10%) - non-GCB 
R NA NA NA NA NA NA NA NA -(30%) NA NA 
3 
P - - -(10%) +(50%) -(60%) +(80%) 90% +(90%) +(90%) - non-GCB 
R NA NA NA NA NA NA NA NA -(20%) NA NA 
4 
P - - -(20%) +(40%) -(25%) +(90%) 75% +(100%) -(5%) NA non-GCB 
R NA NA - NA NA +(90%) NA +(90%) NA NA non-GCB 
5 
P - - +(80%) +(80%) - -(25%) 80% +(80%) -(20%) NA GCB 
R - - -(20%) +(60%) -(30%) +(90%) 95% +(100%) -(15%) NA non-GCB 
6 
P - NA NA NA NA NA 80% +(100%) NA NA na 
R - - - -(2%) +(75%) +(85%) 95% +(100%) +(40%) NA non-GCB 
7 
P + - NA +(65%) - - 80% -(10%) NA NA GCB 
R + - +(70%) +(30%) - -(5%) 55% -(15%) +(40%) NA GCB 
8 
P - + +(40%) NA -(40%) +(80%) 65% +(100%) -(15%) - non-GCB 
R - - +(35%) +(100%) -(15%) +(70%) 70% -(10%) -(35%) NA non-GCB 
9 
P - - +(70%) +(30%) -(50%) +(80%) 90% +(80%) +(40%) - non-GCB 
R - - - +(30%) -(25%) +(50%) 70% -(50%) -(25%) NA non-GCB 
10 
P - + +(70%) -(15%) -(50%) +(75%) 70% -(15%) -(15%) NA non-GCB 
R -(15%) - +(70%) +(30%) -(60%) +(60%) 60% -(10%) -(15%) NA non-GCB 
11 
P - + -(20%) +(60%) +(80%) +(90%) 70% +(100%) NA - non-GCB 
R NA NA NA -(25%) NA NA 90% NA +(60%) NA NA 
12 
P - - NA -(1%) NA NA 70% -(40%) -(5%) NA na 
R - - - -(25%) -(10%) +(50%) 80% +(70%) -(10%) NA non-GCB 
13 
P - - - +(90%) -(60%) +(100%) 90% +(90%) +(90%) - non-GCB 
R +(80%) - - +(80%) +(90%) +(100%) 90% +(100%) +(90%) NA non-GCB 
14 
P - -(20%) +(70%) +(40%) +(80%) +(80%) 70% -(40%) -(15%) + non-GCB 
R - - - +(60%) +(70%) +(60%) 85% -(40%) -(15%) NA non-GCB 
15 
P - - +(40-50%) -(5%) -(30%) -(15%) 90% +(80%) +(50%) + GCB 
R - - +(40%) -(5%) -(15%) +(65%) 70% NA +(40%) NA non-GCB 
more 
16 
P +(90%) - +(50%) +(80%) +(90%) +(70%) 70% +(90%) -(20%) NA GCB 
R +(100%) +(100%) +(70%) +(90%) - +(80%) 90% +(70%) +(70%) NA GCB 
17 
P - - +(70%) +(100%) +(100%) +(100%) 85% -(50%) +(60%) - non - GCB 
R - - +(90%) +(50%) -(50%) +(85%) 95% NA NA NA non-GCB 
18 
P - - - -(20%) +(100%) +(100%) 95% +(100%) +(60%) - non-GCB 
R +(80%) - - +(70%) 
 
+(60%) 90% +(100%) +(100%) NA non-GCB 
19 
P - +(90%) +(100%) +(90%) -(25%) +(60%) 90% +(70%) +(40%) + GCB 
R - +(90%) +(80%) +(50%) -(30%) +(70%) NA -(10%) -(25%) NA GCB 
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20 
P - - - +(75%) +(70%) +(80%) 75% +(100%) +(60%) NA non-GCB 
R - - - +(60%) +(100%) +(100%) 80% +(60%) -(30%) NA non-GCB 
Total 
P 2/19(11%) 5/19(26%) 10/17(59%) 12/16(75%) 6/18 (33%) 14/18(78%) 80% 14/19(74%)* 9/17(52%) 3/11(27%)  
R 4/16(25%) 3/16(19%) 8/17(47%) 13/17(76%) 4/16(25%) 16/17(94%) 81% 8/15(53%) 8/18(44%) NA  
Non-relapsing 
 
CD10 GCET LMO2 BCL6 MUM1 FOXP1 MIB1 BCL2 C-MYC GATA3 COO 
21 
 
- -(30%) +(100%) +(50%) -(60%) +(80%) 90% -(10%) -(30%) - non - GCB 
22 
 
- -(20%) +(100%) +(90%) +(70%) +(80%) 90% -(40%) -(50%) - non - GCB 
23 
 
- - +(70%) +(45%) -(30%) +(70%) 70% -(60%) -(20%) - non - GCB 
24 
 
- NA NA +(30%) -(60%) NA NA +(100%) NA - NA 
25 
 
+ NA - + +(80%) +(70%) 60% -(30%) -(25%) NA GCB 
26 
 
- - -(15%) -dim(20%) +(70%) +(75%) 80% -(40%) +(70%) - non - GCB 
27 
 
- - - +(30%) +(70%) +(90%) 50% +(90%) -(30%) - non - GCB 
28 
 
NA +(80%) + NA - -(15%) NA NA -(40%) NA GCB 
29 
 
-(15%) - +(100%) +(70%) -(30%) - 75% -(25%) -(40%) + GCB 
30 
 
+ + + +(100%) - - 90% -(30%) +(65%) NA GCB 
31 
 
+dim -(40%) +(100%) +(80%) -(15%) +(50%) NA -(25%) -(40%) NA GCB 
Total 
 
2/10(20%) 2/9(22%) 7/10(70%) 9/10(90%) 4/11(36%) 7/10(70%) 77% 2/10(20%)* 2/10(20%) 1/7(14%)  
Abbreviations: COO – cell of origin; dim – weak positivity; GCB – germinal center B cell-like; NA – not analyzed or not applicable; P – primary, R – 
relapse 
 
 
Table S6. Antibodies used, conditions applied for immunohistochemistry and cut-off scores for evaluation 
 BCL2 BCL6 CD10 C-MYC FOXP1 GATA3 GCET LMO2 MIB1 MUM1 
Clone name SP66 GI191E/A8 SP67 Y69 SP133 L50-823 RAM341 1A9-1 Mib-1 MEQ-43 
Antigen retrieval time* 16‘ 32‘ 24‘ 92‘ 16‘ 32‘ 32‘ 32‘ 24‘ 24‘ 
Incubation time 12‘ 28‘ 16‘ 16‘ 12‘ 32‘ 20‘ 16‘ 16‘ 16‘ 
Cut-off 70% 30% 20% 40% 50% any 60% 30% NA 70% 
*Antigen retrieval was performed in CC1 buffer (Ventana/Roche) 
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Table S7. Genes included into the custom lymphoma NGS panel 
 
 
 
 
 
 
 
  
All exons Hotspots only 
TP53 GNA13 MYD88 KRAS PIK3CA STAT6 DNMT3A 
CDKN2A HIST1H1C EZH2 CARD11 PIK3CD PTPN11 CALR 
IKZF1 MEF2B NOTCH1 CREBBP PIK3R1 IRF4 RHOA 
KMT2D PIM1 SF3B1 IDH2 MTOR BCL10 SGK1 
TNFAIP3 PAX5 CD79B IDH1 EP300 IKZF3 KLHL6 
ATM PTPN1 BRAF BCL6 MLL3 MCL1 XPO1 
B2M PTEN JAK2 FBXW7 RELN BCL2L11 CCND1 
BCL2 EBF1 KIT STAT3 TET2 MAP2K1 JAK3 
PRDM1 MYC NOTCH2 CD79A TLN2 U2AF1 
 
BTG1 SOCS1 NRAS CELSR2 FOXO1 FLT3 
 
RESULTS 
 
65 
 
Supplementary figures 
 
Figure S1. Criteria for variant exclusion for different analysis applications 
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Figure S2. Morphology of primary and relapse pairs of DLBCL. Case 5 was diagnosed with nodal 
DLBCL with pleomorphic centroblastic morphology, LMO2+ and FOXP1dim, and relapsed 2 years later 
as a clonally related centroblastic DLCBL in the intestine, LMO2dim and FOXP1+, with linear genomic 
evolution and cell of origin (COO) “switch” (for reasons of COO switch see Supplementary description 
on Retention and change of cell of origin in DLBCL relapses). Case 15 was diagnosed with nodal 
DLBCL with centroblastic morphology, EBV+, in the setting of liver transplantation, i.e. monomorphic 
post-transplant lymphoproliferative disorder (PTLD) and its intestinal “relapse” turned out being a 
clonally unrelated and EBV- second monomorphic PLTD. Case 18 was diagnosed with DLBCL of the 
eye ball (subretinal spread) with centroblastic morphology and relapsed 12 years later as a clonally related 
centroblastic DLCBL in a cervical lymph node with branching genomic evolution, retaining its COO. 
Note that based on morphological analysis, COO and time to relapse, no conclusions on clonal kinships 
and genomic progression can be drawn.   
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Figure S3. Evidence of intra-tumoral genetic heterogeneity in relapsing DLBCL. A. Two adjacent 
parts of the relapse tumor of case 1 were profiled. While the majority of chromosomal copy number 
aberrations match between the two tumor parts, one of them bears additional gains at 8q and focal 
amplifications at 12q. B. Similarly, two parts of the primary tumor of case 5 were profiled (B1). While 
parts of the same biopsy shared a heterozygous deletion 6q, there were also private aberrations of 
chromosomes 3, 8, 18 and X. The subsequent clonally related relapse (B2) evidently originated from one 
of the tumor subpopulations and not form the other.  
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Figure S4. Analysis of immunoglobulin gene rearrangements in case 15. The primary tumor showed an 
oligo-clonal pattern as two fragments of different sizes were amplified. Sequencing analysis showed that 
one of these rearrangements (peak B 259bp) was non-productive, suggesting that it represented the 
second IG allele of the dominant lymphoma clone. At relapse, one dominant rearrangement was amplified 
(peak C). Although its size was close to that of the non-productive rearrangement of the primary tumor, 
sequencing analysis showed the usage of different variable genes. These data suggest different clonal 
origin of the primary and relapse occurrences. A minor peak (peak D) at relapse was detected at a size 
close to the productive rearrangement in the primary tumor. However, again variable gene sequences did 
not match and the latter gene also lacked somatic hypermutations. It is likely that this rearrangement 
represents part of the non-malignant B-cell gene pool.  
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Figure S5. Genetic evolution patterns in relapsing DLBCL continued from Figure 3. Distance plots of 
cases with early-divergent/branching (A) and late-divergent evolutionary pattern (B). Numbers inside 
circles represent a combined count of mutations and copy number aberrations in the respective 
population. Circle sizes are scaled according to the number of genetic alterations. Dashed purple area 
symbolizes the time from putative divergence of populations till occurrence of primary lymphoma, which 
is unknown. Red – genetic alterations unique to primary tumor. Blue – genetic alterations unique to 
relapse. Grey circle – putative common progenitor. The “genetic distance” from the common progenitor 
is plotted on the y axis; at the top of the x axis for the primary tumor, at the bottom – for the relapse.   
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3.2 Extracavitary primary effusion lymphoma: clinical, morphological, 
phenotypic and cytogenetic characterization using nuclei enrichment 
technique. 
 
Juskevicius D., Dietsche T., Lorber T., Rufle A., Ruiz C., Mickys U., Krasniqi F., Dirnhofer S., 
Tzankov A. 
 
 
-Research article- 
Published in Histopathology, 2014 
 
 
Contribution: I developed a FFPE nuclei-enrichment technique, performed the experiments, 
analyzed data, prepared figures and wrote the manuscript 
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3.3 Follicular lymphoma transformation into histiocytic sarcoma: 
indications for a common neoplastic progenitor 
 
Brunner P., Rufle A., Dirnhofer S., Lohri A., Willi N., Cathomas G., Tzankov A., Juskevicius 
D. 
 
-Letter to the editor- 
Published in Leukemia, 2014 
 
 
Contribution: I performed genetic characterization of the case, analyzed data, prepared figures 
and wrote major parts of the manuscript 
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3.4 Clinical, morphologic, phenotypic, and genetic evidence of cyclin D1-
positive diffuse large B-cell lymphomas with CYCLIN D1 gene 
rearrangements 
 
Juskevicius D., Ruiz, C., Dirnhofer S., Tzankov A. 
 
 
-Research article- 
Published in American Journal of Surgical Pathology, 2014 
 
 
Contribution: I performed the experiments, analyzed the data and wrote the manuscript 
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3.5 Array CGH-based analysis of post-transplant plasmacytic hyperplasia 
reveals 'intact genomes' arguing against categorizing it as part of the 
post-transplant lymphoproliferative disease spectrum. 
 
Menter, T, Juskevicius D., Tzankov A. 
 
 
-Letter to the editor- 
Published in Transplant International, 2014 
 
 
Contribution: I performed plasma cell enrichment, aCGH of sorted populations and analysis of 
genetic data 
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3.6 Comprehensive phenotypic characterization of PTLD reveals 
potential reliance on EBV or NF-κB signaling instead of B-cell receptor 
signaling 
 
Menter T., Dickenmann D., Juskevicius D., Steiger J., Dirnhofer S., Tzankov A. 
 
 
-Research article- 
Published in Hematological Oncology, 2016 
 
 
Contribution: I performed clustering analysis of immunohistochemical data, wrote the 
respective section in materials and methods and produced figure 1. 
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3.7 Lenalidomide monotherapy leads to a complete remission in 
refractory B-cell post-transplant lymphoproliferative disorder 
 
Läubli H., Tzankov A., Juskevicius D., Degen L., Rochlitz, L., Stenner-Liewen F. 
 
 
-Letter to the editor- 
Published in Leukemia & Lymphoma, 2015 
 
 
Contribution: I performed genetic characterization of the investigated case and copmpsed part 
B of the Figure 1. 
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3.8 Multiparameter analysis of homogeneously R-CHOP-treated diffuse 
large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic 
biomarkers: report of the prospective SAKK 38/07  
 
Tzankov A., Leu N., Muenst S., Juskevicius D., Klingbiel D., Mamot C., Dirnhover S. 
 
-Research article- 
Published in Journal of hematology & oncology, 2015 
 
 
Contribution: I performed aCGH analysis of CD5-positive DLBCL cases, produced Figure 3 
and formatted the manuscript 
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4. DISCUSSION 
4.1 Clonally-unrelated relapses of DLBCL 
Clonally-unrelated lymphoma relapses have been already documented. This was entirely based 
on investigation of IG heavy and light chain rearrangement or detection of common translocation 
breakpoints or both. Generally, V(D)J rearrangements take place early in B-cell development and 
represent a robust clonality marker. However, it was shown in CLL that tumor-initiating genetic 
lesions can occur prior to IG rearrangement
201
. Such events might represent earliest markers of 
clonal origin and can be overlooked by IG rearrangement analysis. Moreover, such analysis 
provides no information about differences in the general genetic constitution between primary 
and relapsed tumors. Finally, many clonality studies of primary-relapse pairs focused on 
detection of clonal relationship rather than lack of it, therefore many of described allegedly 
clonally-unrelated cases in DLBCL are not sufficiently documented
175,182,202
. This, taken together 
with relatively low percentage of clonally-unrelated relapses, led to discouragement of clonality 
testing in routine of lymphoma diagnostics
184
. 
To my best knowledge, our study is the most comprehensive demonstration of clonally-unrelated 
DLBCL recurrence so far. In addition to standard clonality analysis by multiplex PCR and 
sequencing, which showed clear usage of different IG gene segments for the productive VDJ 
rearrangements in 2 out of 3 detected clonally-unrelated cases (out of the studied collective of 20 
DLBCL pairs 3, i.e. 15%, displayed clonally unrelated relapses), we also contrasted copy 
number and mutational profiles between the investigated two tumor episodes of the same patient. 
This analysis unequivocally demonstrated different genetic constitution of primary and relapses. 
Moreover, it advantageously clarified clonal relationship in one other case, where V(D)J 
rearrangement could not be amplified. Despite complex genomes in multiple cases, the clonally 
unrelated tumors had no shared genetic lesions. Instead each tumor showed a very individual 
profile of genome-wide chromosomal imbalances and nucleotide-level variations suggesting 
separate clonal origin and independent genomic evolution.  
Such unequivocal demonstration demands attention to the clinical aspects of clonally-unrelated 
relapses as previously explained (see introduction). This need is especially highlighted by 
exceptional clinical courses of two patients in our cohort. In one patient clonally-unrelated 
DLBCL recurrence did not respond to rituximab and rescue chemotherapy but was treated 
successfully with lenalidomide monotherapy. The tumor was eradicated and the patient still 
enjoys a long-lasting clinical remission
203
. Another patient suffered from primary testicular 
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DLBCL followed by clonally-unrelated DLBCL of the central nervous system. The CNS tumor 
was successfully treated with high-dose chemotherapy. In both cases such favorable outcomes 
would bona fide not be expected if patients had clonally-related, treatment-resistant DLBCL 
relapses.  
 
4.2 DLBCL relapses occur via two distinct genetic evolution patterns  
Until recently, before the recognition of a substantial genetic heterogeneity in cancer, tumor 
evolution was understood as a linear, step-wise process, during which accumulation of genetic 
lesions leads to an uncontrolled cell growth and malignancy. According to this model evolution 
occurs in one direction i.e. from the intact germline genome towards an aberrant cancer genome, 
with numbers of lesions increasing in the later. Likewise, until recently lymphoma relapses, even 
after a prolonged period of remission, were regarded as direct outgrowths of the primary tumor, 
assuming that all genetic alterations that were present in it are directly passed to the relapse. 
Therefore a relapse was considered to be a more evolutionary advanced stage of the primary 
tumor. This was supported by a stable detection of some selected genetic aberrations (e.g. 
classical drivers of lymphomagenesis such as BCL2 or CYCLIN D1 translocations) throughout 
the whole history of the individual disease. The lack of ability to investigate the entirety of 
tumor’s genetic landscape prevented from looking deeper into this issue.  
The detection of at least two different genetic evolution patterns of clonally-related DLBCL 
relapse in this work, namely 1) early-divergent/branching evolution and 2) late-divergent 
evolution by aCGH and targeted sequencing, contradicts the linear scenario of lymphoma 
development. Rather, it points towards a model of clonal growth and selection, which seems to 
be nearly universal in cancer
204,205
. Similar evolutionary patterns were detected in a paired 
DLBCL cohort by deep-sequencing of IGH gene somatic hypermutations
175
. Moreover, non-
linear evolution and the phenomenon of early and late divergence were documented by various 
approaches in other lymphoid neoplasms such as follicular lymphoma
179,180,200,206–209
, multiple 
myeloma
210
, mantle cell lymphoma
211
 as well as in investigations of genetic differences between 
primary tumor and metastasis in carcinomas
212–214
.  
Early-divergent/branching evolution pattern (Figure 10a) is characterized by high genetic 
dissimilarity between primary and relapsed tumors. Primary tumors in our study had private 
genetic alterations, most importantly homo- or heterozygous deletions, which are not detectable 
at relapse, even at the very low frequency. However, despite this dissimilarity paired samples 
always have a variant number of shared identical somatic genetic alterations proving their clonal 
origin.  
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Late-divergent evolution pattern (Figure 10b) most closely resembles the linear mode of tumor 
evolution, as most of genetic aberrations are shared between primary and relapse. However, also 
in this mode the majority of diagnostic samples show low number of variant somatic mutations, 
detected by targeted NGS, which are not detectable in relapses suggesting a limited degree of 
independent evolution. 
In our study 6/20 (35%) of cases evolved from an early common progenitor and showed a 
branching evolution pattern. The frequency distribution between early- and late-divergent 
patterns of genetic evolution varies greatly in different studies (Table 2). This variation can be 
attributed to small collective sizes, heterogeneous criteria for inclusion, different methodologies 
as well as inherent differences in relapse/progression profiles between different types of 
lymphoid neoplasms.  
 
 
 
Figure 10. Schematic representation of two proposed patterns of genetic evolution in relapsing DLBCL. 
Different colors represent genetically distinct clones that possess private genetic alterations due to independent 
genome evolution. A. In the early-divergent/branching scenario, the divergence occurs early in tumor 
development. The majority of subpopulations stagnate but one clone eventually acquires the effective 
combination of drivers, expands and gives rise to a heterogeneous primary tumor. The dominant population is 
exterminated by the treatment, however an intrinsically resistant clone exists and gives rise to a DLBCL 
relapse. B. In the late-divergent/linear evolution scenario, DLBCL initially possesses a strong driver 
combination (e.g. BCL2 and C-MYC “double hit”). Therefore neoplastic cells grow fast and unrestricted, 
giving rise to a homogeneous primary tumor. Such a tumor is almost exterminated by the treatment but an 
acquired resistance emerges. The resistant subclone already has drivers of effective growth and proliferation 
and rapidly replenishes the tumor mass giving rise to a DLBCL relapse. 
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Table 2. Frequencies of evolutionary patterns detected in other studies of relapsing lymphoma 
 
aCGH – array-comparative genomic hybridization; DLBCL – diffuse large B-cell lymphoma; FL – follicular 
lymphoma; MCL – mantle cell lymphoma; MM – multiple myeloma; NGS – next generation sequencing; SHM seq 
– sequencing of somatic hypermutations in IG genes; WES – whole exome sequencing 
 
Methodological considerations 
We have chosen a strategy of genomic profiling at three different levels, namely IGH 
rearrangement analysis, genome-wide assaying of chromosomal copy number aberrations and 
targeted detection of mutations in the frequently affected genes in lymphomas. It proved 
advantageous for robust identification of evolutionary patterns. Analysis of each of the datasets 
separately showed that important evolutionary and biological aspects of relapse development 
could be missed. For example, DNA copy number analysis alone would have overlooked late-
divergence in many cases and misclassified them as examples of relapse via either linear genetic 
evolution or no genetic progression. This potential oversimplification is prevalent in other 
comparable studies, where aCGH was the only method utilized
200,210
. This shortcoming of aCGH 
is explained by the fact that chromosomal aberrations represent large-scale genomic alterations 
occurring seldom compared to single nucleotide mutations and thus providing only a crude 
resolution for the analysis of evolutionary relationships. On the other hand, targeted sequencing 
alone queries functionally important, but structurally negligibly small portion of the genome and 
thus can overlook important events happening outside of the pre-defined regions.  
The lack of patient-matched germline controls in this study represented an important challenge in 
sequencing data analysis. It is known that mutations in coding regions of cancer-relevant genes 
can be a part of patient-specific germline variation. On the other hand, mutations, which are 
generally classified as germline variations in genetic databases, may be of somatic origin in a 
Study Year 
Early-
divergent 
Late-divergent Neoplasm Methods used 
Okosun et al.
179
 2014 4(12.5%) 28(87.5%) FL WES, Targeted NGS 
Pasqualucci et al.
180
 2014 10(83.3%) 2(16.6%) FL WES, Targeted NGS 
Jiang et al.
175
 2014 6(46.1%) 7(53.8%) DLBCL WES, SHM seq (NGS) 
Bea et al.
215
 2013 2(33.3%) 4(66.7%) MCL WES 
Carlotti et al.
207
 2009 12(66.7%) 6(33.3%) FL SHM seq 
Green et al.
216
 2013 1(50%) 1(50%) FL WES 
Ruminy et al.
208
 2008 0(0%) 6(100%) FL SHM seq 
Magrangeas er al.
217
 2012 8(33,3%) 16(66,6%) MM aCGH 
Eide et al.
200
 2010 29(80,5%) 7(19,5%) FL aCGH 
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particular patient
218
. Therefore, specific attention has to be paid to the process of somatic 
mutation detection in tumor-only samples. False-positives and false-negatives can hamper the 
correct interpretation of the evolutionary relationship. To mitigate this risk we used several 
strategies to exclude germline variants in our study. First, since bulk tumors were sequenced, 
they invariably had a fraction of infiltrating non-malignant cells. Therefore, all mutations shared 
between primary and relapse, which had variant allelic frequency (VAF) indicative of perfect 
hetero- or homozygosity, ~50% and ~100%, respectively, were excluded. Copy number of the 
mutation-affected region was also included in this consideration. Second, we excluded variants 
that are listed in dbSNP database but not included in other databases of somatic variants in 
cancer (e.g. COSMIC). Third, in evolutionary analysis, a case was allocated to one or another 
evolutionary pattern based on the overall results of all three profiling approaches. Therefore the 
potential risk of false-positive or false-negative mutations influencing classification was 
minimized  
 
Implications of distinct genetic patterns of DLBCL relapse 
The discovery of two distinct evolution patterns at relapse raises additional questions and offers 
basis for new hypothesis generation about various aspects of lymphoma biology. Such topics 
include considerations regarding tumor heterogeneity, timing of tumor growth, mechanisms of 
resistance and potential for improved therapy design. 
 
Relapse pattern as marker for genetic heterogeneity of the primary tumor 
It has been suggested, that relapse pattern can potentially correlate with the degree of 
intratumoral heterogeneity of a pre-diagnostic or diagnostic tumor
211,219
. Primary tumors that 
relapse via the late-divergent mode of evolution would expectedly be more homogenous and 
composed of one dominant clone. In contrast, primary tumors of cases where relapse occurred 
via late-divergent/branching evolution could have a more complex subclonal structure with a 
dominant clone accompanied by minor clones that are the product of branching tumor evolution 
in early tumor development. Intratumoral heterogeneity is shown on individual cases in 
DLBCL
220
 and we have also detected evidence of it in multiple samples of our cohort (Figure S3 
in section 3.1). It has been shown in CLL that the presence of subclonal populations at 
presentation is an independent risk factor of disease progression
221
. However, this issue was not 
addressed in DLBCL and needs additional dedicated studies to uncover the true significance of 
this phenomenon. 
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Implications to mechanisms of therapy resistance  
It is also possible that two different evolutionary patterns represent two distinct mechanisms of 
resistance. Late-divergence can represent a spontaneous effort of a tumor to survive under the 
selective pressure of treatment. In this scenario, resistance is not pre-existing, but rather (rapidly) 
acquired at the time of necessity. Mutagenic agents included in chemotherapy regimen might 
provide genetic instability that is required for evolution to occur and to acquire resistance 
mutations guaranteeing clone’s survival. Already having all characteristics required for rapid 
tumor formation, such survivor clones would replenish tumor mass that was lost due to cytotoxic 
effects of the treatment and form an earlier relapse. In contrast, early-divergence is obviously not 
occurring due to therapy pressure, but rather due to limitations imposed by internal organism 
processes such as immune response, lack of nutrients, oxygen, etc. Additionally, genuine tumor 
properties such as higher degree of genomic instability due to defects in DNA repair, increased 
SHM or aberrant mitosis can contribute to early divergence. The resistance to treatment would 
therefore occur as a purely stochastic product of clonal divergence. Genetic lesions that grant 
tumor cell resistance to treatment are not beneficial to clone, which is unexposed to therapeutic 
pressure. They can be even disadvantageous
222
. Therefore such clones proliferate slowly or 
stagnate while others, more efficient ones, thrive and lead to initial lymphoma manifestation. 
Despite small contribution to mass and volume, such populations would confer to lymphoma an 
intrinsic resistance to therapy. Once treatment is applied and the dominant clone is destroyed, 
resistant subpopulation would survive, increase its growth potential by acquiring additional DNA 
lesions and gradually develop relapse tumor. 
 
Potential implications to treatment  
If the above model is feasible and indeed late-divergent and early-divergent relapses can 
correlate with acquired and pre-existing (intrinsic) resistance, respectively, correct identification 
of relapse pattern can have important implications to treatment, especially in the coming era of 
targeted treatment approaches
140
. It has been shown that intrinsic and acquired resistances occur 
via principally distinct cellular mechanisms related to specific types of selective pressures that 
are applied to developing tumor populations. Acquired resistance primarily occurs due to 
mutations in the very same molecule that is targeted. In such scenario initial response to 
treatment is usually observed, until resistance-granting mutations are accumulated. Effects of 
such mutations can be variable and include: 1) increased target’s expression (through 
inactivation of negative regulation loops or gene amplifications); 2) compromised binding of 
drug to a target (specific mutations in drug binding sites); 3) changes modulating target’s activity 
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(mutations in target’s functional domains)223. In contrast, intrinsic resistance to targeted 
treatment is characterized by alterations that are initially present upstream or downstream of 
target’s signaling pathway. Therefore target’s inhibition is not effective as the tumor has a pre-
developed mechanism of circumventing target’s function and delivering important tumorigenic 
signals via alternative pathways. In such scenario, the resistant cell population (possibly a minor 
clone in the context of whole tumor, as discussed earlier) is unaffected by the therapy.  
Both intrinsic and acquired resistance can contribute to relapses. For example, one study reported 
two types of mutations responsible for the acquired resistance to the BTK inhibitor Ibrutinib in 
CLL: 1) mutations in BTK itself that change Ibrutinib-mediated BTK inactivation from 
irreversible to reversible and 2) gain-of-function mutations in phospholipase gamma 2 (PLCγ2), 
which is a downstream phosphorylation target of BTK
224
. Although not directly stated by the 
authors, BTK mutations most obviously represent acquired resistance, while PLCγ2 mutations 
are related to pre-existing resistance in small subpopulation. This hypothesis is strongly 
supported by detection of PLCγ2 mutation in the diagnostic CLL sample at a very low frequency 
in one patient. It is known that intrinsic resistance to Ibrutinib in DLBCL occurs due to the 
presence of L265P mutation in MYD88. Mechanisms of acquired resistance to Ibrutinib in 
DLBCL are still unknown
225
. In conclusion, early-divergent and late-divergent patterns of 
genetic evolution at relapse can provide valuable information about which type of treatment 
resistance is potentially present in the recurrence and can consequently help to design better 
targeted treatment approaches. 
 
Early-divergent tumors are related to later relapses 
We found that DLBCL relapses, which followed the early-divergent/branching mode of 
evolution, took significantly longer time to occur as compared to late-divergent/linear relapses. 
This is in contrast to the results of another study, which didn’t find this association175. 
Importantly, this trend of later relapses was also reported in some studies on follicular lymphoma 
transformation
179
. There are several probable explanations to the delayed relapses seen in cases 
that diverged early. First, the relapse-initiating clones are most likely very small in size; this is 
supported by the fact that relapse-specific mutations are rarely detected in the primary tumor and 
if they are detected, they often have a very small allelic frequency
178,221,226
. Second, such 
subclones need time to acquire additional genetic aberrations that would allow them to increase 
their capacity to proliferate. This argument is supported by data showing that putative common 
progenitors in early-divergent/branching mode of evolution have a small number of genetic 
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lesions, while lymphoma clones, which are “successful” and give rise to detectable tumors are 
often characterized by profound genomic complexity
227,228
.  
 
Poor correlation between evolution time and tumor genome complexity  
Also of interest is the fact early-divergent/branching relapses generally have equal amount or 
less DNA lesions compared to their corresponding primary tumors, despite having had much 
more time to develop (median time to relapse 52 months). This suggests that: 1) tumor 
populations can maintain relatively stable genomes for a long period of time; 2) length of genetic 
evolution does not necessarily lead to increased genetic complexity. It also shows that at least in 
DLBCL, relapses are not associated with large-scale genome rearrangements and catastrophic 
events (genome doubling, chromothripsis, chromoplexy, etc.) as seen in other types of tumors
229–
232
.  
 
Considerations regarding the speed of tumor formation 
It is currently unknown how long does it take on average from the first cancer-initiating mutation 
to clinically-detectable tumor to develop. Some studies suggest that it can be a decade-long 
process, while others demonstrate a very fast and aggressive tumor growth. In a speculative spirit 
one could hypothesize that tumors, which have early-divergent/branching pattern of evolution 
take longer to grow and manifest compared to those, which are late-divergent and thus more 
homogenous at the early stages. The very fact of early divergence points towards limiting factors 
that restrain the growth of a pre-malignant clone, which have to evolve and diversify in order to 
overcome these constraints. The stochastic search of the proper combination of powerful driver 
mutations can be a very long process and thus it can take decades until the clinically detectable 
tumor is formed. On the other hand, homogeneity in early lymphomagenesis (characterized by 
late-divergent evolution) can represent fast and effective growth of lymphoma from the very 
outset of the malignant process. Such pace can be mediated by very early acquisition of powerful 
driver lesions, which give cells a strong competitive advantage. It has been shown, that even if 
two tumors have identical somatic mutations at diagnosis, the order of their acquisition can 
greatly influence the vast majority of tumor features including morphology, aggressiveness and 
importantly – speed of growth216.  
 
4.3 Identification of genetic drivers of DLBCL relapse 
Based on what is known about tumor biology it is reasonable to hypothesize that DLBCL 
relapses occur as a consequence of genetic evolution. Therefore it is conceivable that 
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investigation of exact changes that occur during this evolution should result in identification of 
genetic drivers of the process as well as prognostic, predictive markers and, hopefully, “genetic 
vulnerabilities”, which could be targeted to improve currently available treatments. In our study 
we pursued this strategy by two related lines of action: first, we aimed to identify possible 
genetic events that lead to DLBCL recurrence by investigating matched primary and relapsed 
tumors; second, we acquired genetic profiles of a cohort of primary non-relapsing DLBCL 
(relapse-free for at least 6 years) and compared them to the ones of primaries of DLBCL that 
relapsed. In this way we sought to identify genetic alterations that could predict disease course at 
the time of its detection.  
Due to the lack of matched primary DLBCL samples other comparable studies mostly 
investigated relapsed/refractory tumors only. Although by this approach potentially larger 
cohorts can be collected, it has a significant drawback in that it is nearly impossible to accurately 
differentiate between mutations that have been present in the primary stage and the ones that are 
relapse-specific. This problem can be illustrated by the ambiguous status of MYD88 L265P 
mutations in DLBCL. In our study this mutation was detected exceptionally as heterozygous 
early driver lesion present in both primary and relapsed tumors of the same patient. In contrast, 
an earlier DLBCL genome sequencing study by Morin et al. reported that classic driver events 
such as mutations of MYD88, CD79A/B and EZH2 can also be sub-clonally present within 
primary DLBCL. Therefore MYD88 mutation can be both an early and a late event in DLBCL 
development but this discrimination is highly problematic in cases where only relapsed tumor 
samples are examined. Additionally, the existence of a significant share (~15%) of clonally-
unrelated relapses in DLBCL, as shown in our and other studies, represent a risk that genetic 
lesions in de novo DLBCL, which are only clinically present as “relapses” but indeed represent a 
second independent disease of the same diagnostic category in the same patient, could be 
misclassified as relapse-specific. The above mentioned shortcomings can partially explain why 
there is only limited overlap between 4 genomic studies of DLBCL relapses so far (Table 3). 
This modest overlap can also be attributed to the intrinsic high heterogeneity of DLBCL that 
small-scale genetic studies fail to encompass entirely. 
It has recently been demonstrated that in addition to genetic mechanisms, changes of the 
epigenetic landscape can also play a role in DLBCL relapse. Pan et al. found that relapses have 
significantly decreased intra-tumoral methylation heterogeneity
233
. Further they showed that 
higher intra-tumoral methylation heterogeneity in a primary tumor correlate with its tendency to 
relapse after treatment. Unsurprisingly for a genome-wide study, multiple recurrently hypo- or 
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hypermethylated genes were identified. The functional significances of these are unclear as they 
were not implicated in cancerogenesis before thus they remain a topic for further investigation. 
Table 3. Overview of findings in four studies on the genetic background of DLBCL relapse 
 Jiang et al.175 Mareschal et al.177 Morin et al.178 Juskevicius et al.  
Study design 
WES of 7 matched 
primary-relapse pairs and 
matched germline 
samples. Mutations 
confirmed by targeted 
sequencing 
WES of 14 rrDLBCL 
and their germline 
controls. Mutation 
frequencies compared to 
published DLBCL 
exome data 
WES of 38 rrDLBCL 
and their germline 
controls. Targeted 
sequencing of 12 
matched diagnostic 
samples. Mutations 
frequencies compared to 
138 diagnostic DLBCL 
aCGH and targeted NGS 
of 20 matched primary-
relapse pairs and 11 
primary non-relapsing 
DLBCL 
Genes mutations, 
implicated in early 
lymphomagenesis 
KMT2D, EP300 NA NA 
KMT2D, MYD88, CD79B, 
PIM1 
Gene mutations 
implicated in 
DLBCL relapse 
CD58, B2M, ARHGEF7, 
PLCB2, IL9R 
ABC: MYD88, CD58, 
TBL1XR1, IRF4. GCB: 
BCL2, MEF2B, 
DUSP2, NFKBIA, 
PIM1, KMT2D, GNA13. 
PMBCL: SOCS1, 
STAT6, TNAIFP3;B2M, 
ITPKB, NFKBIE 
TP53, FOXO1, MLL3, 
NFKBIZ, STAT6, MYC, 
MLL3, MPEG1, 
CCND3, MYD88, 
FOXO1, TNFRSF14, 
CARD11, B2M, 
MEF2B, ARID1A, 
TBL1XR1, NFKBIE, 
SOCS1, CD79B, BCL2  
KMT2D, MEF2B, gain 
chr10p15.3-13(GATA3, 
PRKCQ)  
GO and pathways 
associated with 
relapses. 
Apoptosis; 
transmembrane receptor 
tyrosine kinases; calcium 
channel activity; p53 
binding 
NF-κB signaling, 
sucrose degradation, 
tryptophan degradation, 
JAK-STAT signaling, 
meiosis; epigenetic 
regulation; S1P2 
signaling pathway 
JAK-STAT signaling NA 
Non-relapsing 
DLBCL-specific 
lesions 
 
NA NA NA 
Mutations: SOCS1, RELN. 
Deletions:CYP7B1. 
Multiple gains: REL  and 
other (see Table 2 in 
section 3.1)  
 
GO – gene ontology term; NA – not accessed; rrDLBCL – relapse/refractory DLBCL; WES- whole exome 
sequencing. Genes that were found mutated in at least two different studies within the same category are marked in 
bold. 
 
All combined, it appears that we are now just at the beginning of understanding the genetic and 
epigenetic mechanisms of DLBCL relapse. Since there is a lack of suitable specimens to conduct 
large-scale comprehensive studies on human samples, it could be worthwhile to pursue 
alternative strategies. One potential opportunity would be to conduct the most comprehensive 
studies of selected single cases at multiple currently accessible levels (i.e. genome, epigenome, 
transcriptome, proteome, metabolome), attempting to develop a state-of-the-art individual tumor 
(tumor pair) profile that would reveal at great depth the inner workings and vulnerabilities of it. 
Another, complementary strategy could be DLBCL relapse simulation in currently available or 
newly established animal models
124,139
. In this way potential relapse-causing events could be 
isolated, functionally tested and then screened by focused assays on human sample cohorts. In 
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addition, potential relapse-causing DNA lesions identified in human DLBCL tumors could be 
functionally tested in advanced modelling systems. 
 
4.4 Branching evolution and hematopoietic plasticity of follicular 
lymphoma relapse and its transformation to histiocytic sarcoma 
In a single case study we investigated the clonal relationship and genomic evolution of a 
follicular lymphoma (FL) and its transformation to histiocytic sarcoma. Four samples of one 
patient (primary FL, two relapses at different timepoints and a histiocytic sarcoma) were 
available for comprehensive characterization by histological, clonality, translocation and DNA 
copy number analysis. It is the most comprehensive investigation of such clinical setting so far, 
providing several important insights about the evolutionary development of two distinct 
hematolymphoid neoplasms in the same patient.  
First, our study confirmed multiple previous observations that dendritic/histiocytic neoplasms 
and a preceding indolent lymphomas are clonally related
234–236
. Tumors of both cancer types 
derived from the same B-cell precursor as evident by shared IGH rearrangement and identical 
t(14;18) translocation breakpoints. It is an important finding since histiocytes belong to a distinct 
hematopoietic lineage and “spontaneous” histiocytic sarcomas usually lack clonal IG gene 
rearrangements and/or common translocations observed in lymphomas
237
.  
Secondly, our report challenged the most favored hypothesis that attempts to explain the arousal 
of histiocytic sarcomas in the context of indolent lymphomas, namely a transdifferentiation of a 
lymphoma B-cells to a histiocyte. The genetic data acquired from both tumor types was 
incompatible with this hypothesis. The FL of our patient had an aberrant and relatively complex 
genome with multiple gains and deletions of genetic material. In contrast, the subsequent 
histiocytic sarcoma had a completely intact genome, at least from the perspective of unbalanced 
copy number changes. Moreover, mutational analysis by targeted sequencing of the most 
frequent cancer genes yielded no significant somatic alterations that could be reliably related to 
sarcoma development. This suggests a branching evolution of FL and histiocytic sarcoma. The 
divergence from a common progenitor should have taken place after the pre-B-cell stage of B-
cell development, when IGH rearrangements and chromosomal translocations, particularly 
t(14;18) occurred, but before the acquisition of any chromosomal imbalances by the prospect FL 
clone. It is known that the majority of FL arise from t(14;18)-bearing GC centroblasts that 
acquired this translocation at the early B-cell developmental stage due to aberrant functions of 
the IGH rearrangement machinery, and many of their genetic defects are related to aberrant SHM 
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and CSR. Therefore it is intriguing to think that some abnormal, probably t(14;18)-driven 
divisions of the very early progenitor B-cell resulted in some daughter cells changing their 
lineage and converting into histiocyte-like cells. 
Such scenario is not entirely compatible with the classical dichotomous model of hematopoiesis, 
which states that commitment to lymphoid and myeloid lineages occur in early stages of 
hematopoiesis and that common lymphocyte progenitors (CLP) as well as common myeloid 
progenitors (CMP) possess a high level of lineage fidelity
238–240
. Instead, it fits well with a 
postulated alternative myeloid-based model, which argues that later lymphocyte developmental 
stages retain plasticity and capability to differentiate into cells of the myeloid lineage
241
. Indeed 
it is known that early T-cell progenitors retain myeloid differentiation potential in mice
242
. 
Moreover, it has been shown in vitro that in the absence of Pax5, murine pre-B-1 cells, already 
bearing D-J rearranged IGH genes, could differentiate into various hematopoietic cell types, 
including macrophages
243
. Suppression of PAX5 is thought to be crucial for early B-cell 
plasticity
7
. Interestingly, the FL cells in our case expressed PAX5 while the histiocytic sarcoma 
was PAX5-negative. Unfortunately, we didn’t have the opportunity to look for mutations in the 
coding part of PAX5 gene and it’s regulators at the time of the project so the role of this B-cell 
fate controller in our case remains unclear.  
In most of the studies, early B-cell plasticity has been demonstrated on animal models in 
laboratory conditions. Our case is one of the few proofs of such plasticity in humans. It is most 
likely that this plasticity is physiologically constrained, but can be reactivated as a part of 
aberrant cell processes during tumorigenesis.  
In agreement with other FL studies and also with our DLBCL study discussed earlier, FL 
relapses in this single case developed from a common progenitor following an early-
divergent/branching evolution scenario. Exceptionally high quality aCGH data acquired from 
this patient samples allowed us to identify at least two subpopulations in the primary tumor with 
approximate frequencies of 70% and 30%. Analysis of chromosomal copy numbers in two 
recurrences at two distinct time points suggested that relapses evolved from the less frequent 
subpopulation. The more frequent clone was probably made extinct by the initial treatment. This 
data suggests an intrinsically present treatment resistance in a subpopulation of the primary 
tumor leading to an outgrowth after therapy. Interestingly, despite more than two-year period 
between the second and third relapse, no private chromosomal imbalances were observed in the 
former, indicating that after a bottleneck, imposed by treatment-induced selection of a resistant 
subclone, FL relapses tend to be more homogenous. 
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4.5. Sorting of FFPE-tissue derived tumor nuclei enables genetic 
investigation of rare cancer cell populations 
The majority of human tumors almost entirely consist of proliferating malignant cancer cells, 
which are admixed with smaller percentages of normal tumor-infiltrating immune cells and 
stromal cells. However some tumors have this morphological feature reversed i.e. malignant 
cancer cells constitute only a small percentage of all tumor cells. In such cases individual cancer 
cells are scattered throughout the affected tissue and are surrounded by tumor-infiltrating cells. 
In extreme cases the frequency of malignant cancer cells can be as little as 0.5%. Within the 
group of hematolymphoid neoplasms, this morphological feature is mostly characteristic to 
classical Hodgkin lymphoma (cHL) and T-cell/histiocyte-rich B-cell lymphoma, but it can also 
be encountered in other cancer types in individual cases
72
. 
Genetic investigation of such tumors requires a prior enrichment of malignant cells because 
otherwise tumor-specific genetic features are masked by the genome readout of normal cells and 
are undetectable. Laser-capture microdissection (LCM), fluorescence-assisted flow sorting 
(FACS), antibody-conjugated magnetic beads and other methods are used for enrichment in such 
instances. However, the choice of methods is extremely limited when cells need to be enriched 
from FFPE tissues. In most such cases LCM is applied since the majority of antibody-based 
approaches are designed for fresh cells and do not function with fixed archival material. The 
main drawback of LCM is that laser energy applied to cells during microdissection further 
fragments the already-fragmented DNA from FFPE tissues, rendering it unsuitable for many 
downstream applications
244
. Further it is a low-throughput method, making cell enrichment very 
labor- and time-intensive. 
The above mentioned reasons motivated us to develop protocols for rare cell extraction from 
archival tissues by FACS. We took advantage of available monoclonal antibodies that are used in 
routine immunohistochemical diagnostics and which were optimized to bind epitopes on FFPE 
tissues. We focused our efforts on establishing FACS enrichment based on nuclear and 
cytoplasmic markers such as MUM1, CD30, PAX5 and the HHV-8 viral nuclear protein 
LANA1, which are commonly expressed by lymphoid neoplasms having low tumor cell 
frequencies. 
Protocols for nuclei extraction using enzymatic digestion were previously published and used 
mainly for determination of tumor DNA content by staining cell nuclei with propidium iodide or 
DAPI
245–248
. We modified these protocols to enable staining with specific antibodies. 
Importantly, we avoided the usage of broad-specificity proteases such as pepsin and trypsin but 
rather used more specific ones such as collagenase, dispase and hyaluronidase to avoid over-
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digestion and cleavage of the epitopes of interest. Immunohistochemical staining of nuclear 
suspensions proved that the epitopes were conserved during the extraction process, retained their 
antigenicity and are recognized by specific monoclonal antibodies (Figure 11). 
 
Marker-based sorting of FFPE-derived nuclei has previously been performed for carcinoma cell 
enrichment making use of their specific (compared to the intermingled non-neoplastic stroma 
cells) cytokeratin expression
245,249
. In lymphomas successful staining of cells with antibodies 
against CD79A, CD3 and CD20 has been demonstrated
250
. Using staining for the HHV-8 viral 
LANA1 protein we sorted HHV-8-positive tumor cells of solid variants of primary effusion 
lymphomas
251
. Staining for MUM1 allowed us to enrich plasma cells in 5 samples of post-
transplant plasmacytic hyperplasia that only partially affected tonsils and lymph nodes
252
. In both 
studies at least 10 000 cells-of-interest per case could be collected, allowing robust analysis of 
clonality and copy number aberrations in each of them. This enabled us to answer disease-
specific clinical and biological questions, which could otherwise not be addressed.  
We have also demonstrated the potential of this technique to enrich Hodgkin and Reed-Sternberg 
(HRS) nuclei of cHL from FFPE tissues
253
. Until now only cell lines and limited cohorts of fresh 
or fresh-frozen tissues from this neoplasm could be genetically analyzed
254–257
. High-throughput 
enrichment of HRS cells from FFPE tissue will open opportunities for investigation of much 
larger, well-described collections of archived cHL cases. This will without doubt lead to better 
characterization and improved understanding of the genetic basis of this disease. 
Figure 11. Confirmation of specific primary antibody binding to nuclei extracted from FFPE tissues by 
immunohistochemical staining in cases of HHV8+ solid forms of primary effusion lymphomas and 
Hodgkin lymphomas. 
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GENERAL CONCLUSION 
Investigation of the genetic background and evolution of DLBCL relapses 
Investigating matched primary-relapse sample pairs by genome-wide copy number, targeted 
mutational and clonality analysis we unequivocally demonstrated the existence of clonally-
unrelated recurrences in diffuse large B-cell lymphoma (DLBCL). Such unrelated DLBCL 
occurrences arise independently one from another, possibly under the influence of potential 
predisposing factors such as immunosuppression and presence of somatic mutations in the 
healthy hemato-lymphopoiesis. 
Clonally-related DLBCL relapses consistently share some common DNA lesions but follow at 
least two distinct evolutionary scenarios. The early-divergent/branching pattern is characterized 
by a small number of shared genetic alterations, which represent early events in 
lymphomagenesis and large number of stage-specific DNA lesions. Consequently, the genetic 
distance between the postulated common progenitor and the respective primary tumor is large. 
The late-divergent/linear relapse pattern is characterized by a large number of shared genetic 
alterations between the primary and relapse tumors. The primary tumors in this pattern have 
none or very limited numbers of private DNA lesions and therefore the genetic distance to the 
common progenitor is small.  
Based on the observations above it is likely that primary DLBCL tumors, which relapse via the 
early-divergent/branching pattern, have an intrinsic resistance to therapy. In contrast, primary 
DLBCL, which relapse via the late-divergent genetic evolution pattern, acquire resistance after 
treatment is administered. 
Detailed analysis of genetic data from paired tumor samples also revealed recurrently shared 
mutations representing early drivers of lymphomagenesis and recurrent group-specific genetic 
alterations. These events were characteristic to non-relapsing and relapsing primary DLBCL and 
might be linked to treatment susceptibility and the emergence of recurrences, respectively. 
 
Studying transformation of follicular lymphoma (FL) into histiocytic sarcoma: indications 
for a common neoplastic progenitor 
In this one case study we genetically characterized a histiocytic sarcoma occurring in the 
background of follicular lymphoma. My results confirm previous paradoxical observations that 
both FL and histiocytic sarcoma share identical immunoglobulin gene rearrangements and 
t(14;18) translocation, proving their clonal origin. Moreover, distinct copy number aberration 
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patterns allowed us to approximately estimate the divergence time of lymphoma- and sarcoma-
initiating clones. This lead to rare demonstration in humans that B-cells maintain the potential to 
revert their lineage commitment and differentiate into histiocyte-like cells until as late as a pre-B 
developmental stage. 
 
Enabling enrichment and genetic analysis of rare tumor cell populations from archival 
formalin-fixed paraffin-embedded (FFPE) tissues 
We developed and optimized protocols that enable reliable high-throughput marker-based 
enrichment of rare lymphoid tumor cells from FFPE material. Archival tissue cell suspensions 
can be prepared, specifically labelled according to their expression of distinct cellular markers 
and enriched by flow-sorting. This technique enabled us to genetically analyze cases of solid 
variants of primary effusion lymphomas and post-transplant plasmacytic hyperplasias answering 
relevant research questions in each of these two diseases. Moreover, this enrichment method can 
be further refined and applied to enable genetic investigations of other tumor cell-scarce 
lymphoid neoplasms such as classical Hodgkin lymphoma and T-cell/histiocyte rich B-cell 
lymphoma.  
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LIST OF ABBREVIATIONS 
aCGH – array-comparative genome hybridization 
ADM2 – aberration detection method 
AID – activation-induced deaminase 
ARHGEF1 - RHO guanine nucleotide exchange factor 1 
ASCT – autologous stem cell transplantation  
B2M – beta 2 microglobulin 
BAFF – B-cell activator of the TNF-α family 
BAFF-R – BAFF receptor 
BCL2 – B-cell lymphoma 2 
BCR – B-cell receptor 
BLIMP – B-lymphocyte-induced maturation protein 1 
BRCA2 – breast cancer 2 
CARD11 – caspase recruitment domain containing protein 11 
CCND3 – cyclin D3 
CD – cluster of differentiation 
CDR – complementarity-determining region 
CSR – class switch recombination  
CT – computer tomography 
CXCL13 – chemokine (C-X-C Motif) ligand 13 
CXCR5 – chemokine (C-X-C Motif) receptor 5 
DA-EPOCH-R – dose-adjusted etoposide, prednisolone, oncovin, cyclophosphamide, 
hydroxydaunorubicin and rituximab 
DAPI – 4',6-diamidino-2-phenylindole 
DUSP2 – dual specificity phosphatase 2 
EBF1 – early B-cell factor 1 
EBV – Epstein-Barr virus 
EP300 - E1A binding protein p300 
EZH2 – enhancer of zeste homolog 2 
FACS – fluorescence-assisted cell sorting 
FDC – follicular dendritic cells 
FLT3 – Fms-like tyrosine kinase 3 
FOXO1 – forkhead box protein O1  
GATA3 – GATA binding protein 3 
GNA13 – guanine nucleotide binding protein alpha 13 
HHV-8 – human herpes virus 8 
IG – immunoglobulin 
IGH – immunoglobulin heavy chain 
IGV – immunoglobulin gene variable region 
IL – interleukin 
INF-γ – interferon gamma 
IRF – interferon-regulatory factor 
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ITPKB – inositol-trisphosphate 3-kinase B 
Iκβ – inhibitor of NF-κB 
JAK – Janus kinase 
LMO2 – LIM domain only 2 
MLL3 – lysine-specific methyltransferase 2C 
MPEG1 – macrophage expressed 1 
MUM1 – see IRF4 
MYD88 – myeloid differentiation primary response protein 88 
NFKBIA – nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha 
NFKBIE – nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor epsilon 
NFKBIZ – nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor zeta 
NF-κB – nuclear factor kappa B 
NGS – next-generation sequencing 
NOTCH1 – notch homolog 1, translocation-associated 
PAX5 – paired box 5 
PET – positron emission tomography 
PIM1 – Pim-1 proto-oncogene, serine/threonine kinase 
PRDM1 – PR domain zinc finger protein 1 
RAG – recombination activating gene  
R-CHOP – rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone  
REL - V-Rel avian reticuloendotheliosis viral oncogene homolog 
HRS – Hodgkin and Reed-Sternberg cells 
RSS – recombination recognition sequence 
S1PR2 – sphingosine-1-phosphate receptor-2 
SHM – somatic hypermutation 
SOCS1 – suppressor of cytokine signaling 1 
STAT6 – signal transducer and activator of transcription 6 
STK11 – serine/threonine kinase 11 
TCR – T-cell receptor 
TdT – terminal deoxynucleotidyl transferase  
TIR – toll/IL-1 receptor domain  
TNF – tumor necrosis factor 
TNFRSF14 – tumor necrosis factor receptor superfamily, member 14 
XBP1 – X-box-binding protein 1 
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